<allTrials totalCount="1088" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2026-11-13T15:22:10.342719046Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN71452613" publicIdentifierDateAssigned="2026-11-19T13:58:28.928624Z">
    <isrctn dateAssigned="2026-11-19T13:58:28.928624Z">71452613</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>A study to look at the clinical, human  and economic effects on patients who suffer prolonged epileptic seizures</title>
      <scientificTitle>The clinical, humanistic and economic patient burden of prolonged seizures in epilepsy: a prospective observational study in the UK (RWE1597)</scientificTitle>
      <acronym>RWE1597</acronym>
      <studyHypothesis>1. To characterize the population of patients with PS in terms of demographic and clinical characteristics, including diagnostic and medical history, and seizure type(s)
2. To characterize the patient experience of PS events and clinical outcomes over the observation period
3. To describe healthcare resource utilization (HCRU) in patients with PS
4. To assess health-related quality of life (HRQoL) in patients with PS</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
The study is designed to look at patients who suffer from prolonged seizures (PS) in epilepsy.  The study will collect information on the clinical effects (medical outcomes), human effects (effects on everyday life) and economic effects (effects on ability to work) in this group of patients.  

Who can participate? 
Patients aged at least 12 years old who suffer from PS

What does the study involve? 
Patients will be asked to complete questionnaires (three times over a 6-month period) and study diaries capturing seizures for 6 months. These will be completed electronically on a phone or tablet. 

What are the possible benefits and risks of participating? 
There are no benefits from taking part, but the study may collect information which is useful in the treatment of this group of patients in the future.  

Where is the study run from? 
UCB Biopharma SRL (Belgium)

When is the study starting and how long is it expected to run for? 
September 2026 to September 2027

Who is funding the study? 
UCB Biopharma SRL (Belgium)

Who is the main contact? 
Fiona McNulty, fiona.mcnulty@ubc.com</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="49c812a4-01ad-4108-a6bc-a444c9d047f4">
	  <variable>Health-related quality of life</variable>
	  <method>the Patient-Weighted Quality of Life in Epilepsy Inventory (QOLIE-31-P) for adults or Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48) for adolescents</method>
	  <timepoints>baseline, 3 months and 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="70001f8b-4794-40e6-ba56-5cd53e8cd406">
	  <variable>General health status</variable>
	  <method>the EuroQol 5-Dimensions, 5-Levels (EQ-5D-5L) or EuroQol 5-Dimensions, 5-Levels Youth version (EQ-5D-Y-5L)</method>
	  <timepoints>baseline, 3 months and 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a77d6106-607a-4800-b4ac-d11be5627ac6">
	  <variable>Depressive symptoms</variable>
	  <method>the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) or Neurological Disorders Depression Inventory for Epilepsy Youth (NDDI-E-Y)</method>
	  <timepoints>baseline, 3 months and 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="064337ab-5585-46f5-8600-b6c0bd0b0215">
	  <variable>Epilepsy-related stigma</variable>
	  <method>the revised Epilepsy Stigma Scale (rESS) or Epilepsy Stigma Scale for Children</method>
	  <timepoints>baseline and 6 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9a5037ec-d8d1-495d-9da9-866821ec80d1">
	  <variable>Patient-reported experiences and impacts of prolonged seizures</variable>
	  <method>non-validated questionnaires</method>
	  <timepoints>baseline and 3 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c534e040-b08e-43f8-8b59-328d30891c42">
	  <variable>Prolonged seizure characteristics, including seizure frequency, type, duration, associated symptoms, injuries, rescue medication use, recurrence and recovery time,</variable>
	  <method>a seizure diary</method>
	  <timepoints>baseline and monthly from month 1 to month 6</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="03609043-aaa7-45a2-92c3-6c14937bed71" approvalStatus="approved" statusDate="2026-08-25T00:00:00.000Z">
	  <committeeName>Proportionate Review Sub-committee of the South West - Central Bristol Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place
Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SW/0100</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN71452613</doi>
      <eudraCTNumber/>
      <irasNumber>370112</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="8a558722-0d19-4a74-8dad-490bf2d7f847" numberType="iras" canonicalSecondaryNumber="IRAS370112">370112</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Prospective observational study</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-09-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="44574af5-72c9-4513-b070-2c705de9e526">
	  <name>The Royal Wolverhampton NHS Trust</name>
	  <address>New Cross Hospital
Wolverhampton Road
Heath Town</address>
	  <city>Wolverhampton</city>
	  <state/>
	  <country>England</country>
	  <zip>WV10 0QP</zip>
	  <rtsId>RL4@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c2274a0c-316a-49ec-9900-f6f3c5445de4">
	  <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
	  <address>Freeman Hospital
Freeman Road
High Heaton</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE7 7DN</zip>
	  <rtsId>RTD@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="96159010-079b-4178-8335-6674ceae55a8">
	  <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
	  <address>Northern General Hospital
Herries Road</address>
	  <city>Sheffield</city>
	  <state/>
	  <country>England</country>
	  <zip>S5 7AU</zip>
	  <rtsId>RHQ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5decd3eb-3b5d-4b44-862d-5e1169c8d44c">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>RRV00@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Is at least 12 years old at the time of providing assent/consent for study participation
2. Has a documented medical diagnosis of epilepsy
3. Is at risk of prolonged seizures (PS) according to the REST definitions based on physician’s clinical impression of seizure history and disease status
4. Has had at least one PS event within the last month prior to study enrolment evaluation
5. Patient has sufficient cognitive ability to understand the Patient-Reported Outcome questionnaires and seizure diary items and to provide their own answers. Patients may receive non-directive assistance limited to technical or physical support (e.g., typing or navigating the device), provided that all response content is generated by the patient
6. Informed consent and, where applicable, assent for participation will be obtained in accordance with applicable national regulations and the procedures approved by the Ethics Committee
7. The patient, and caregiver/LAR if applicable, has sufficient command of English language to understand the study information and requirements</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="12.0">12 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Is enrolled in any clinical trial at the time of assent/consent for study participation
2. Has a history of presence of known non-epileptic seizures which cannot be distinguished from qualifying epileptic seizures</exclusion>
      <recruitmentStart>2026-09-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-03-09T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Epilepsy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Observational study including questionnaires and patient diaries. Patients will receive usual care. Patients will be asked to complete questionnaires (three times over a 6-month period) and study diaries capturing seizures for 6 months. These will be completed electronically on a phone or tablet.</description>
	<interventionType>Other</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>3eb4defc-4223-432d-9d89-56418f4f25cb</funderId>
      <contactId>048cb64b-e3f3-4834-adfc-6f69b7cb54ea</contactId>
      <contactId>2ff37bbd-ae19-4d80-9a76-d7b36b9ebd3c</contactId>
      <sponsorId>d9763b11-2168-4b63-90fb-8017c89990ca</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="048cb64b-e3f3-4834-adfc-6f69b7cb54ea">
    <title>Dr</title>
    <forename>Craig</forename>
    <surname>Heath</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Neurosciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde</address>
      <city>Glasgow</city>
      <state/>
      <country>United Kingdom</country>
      <zip>G51 4TF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 2012374</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Craig.Heath2@nhs.scot</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="2ff37bbd-ae19-4d80-9a76-d7b36b9ebd3c">
    <title>Ms</title>
    <forename>Fiona</forename>
    <surname>McNulty</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>23 Spring Meadows</address>
      <city>Warrenpoint</city>
      <state/>
      <country>United Kingdom</country>
      <zip>BT34 3SU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)7740651840</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fiona.mcnulty@ubc.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="d9763b11-2168-4b63-90fb-8017c89990ca">
    <organisation>UCB</organisation>
    <sponsorType/>
    <commercialStatus>Commercial</commercialStatus>
  </sponsor>
  <funder id="3eb4defc-4223-432d-9d89-56418f4f25cb">
    <name>UCB</name>
    <fundRef>http://dx.doi.org/10.13039/100011110</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-11T08:57:54.009121248Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN60674326" publicIdentifierDateAssigned="2026-11-11T15:11:25.001018Z">
    <isrctn dateAssigned="2026-11-11T15:11:25.001018Z">60674326</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Using AI to improve recruitment of people with intellectual disabilities and autistic people to research</title>
      <scientificTitle>Using AI to improve recruitment of people with intellectual disabilities and autistic people to research</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Further develop the accessible AI chatbot from the Phase 1 ROK-UK collaboration through co-design with people with intellectual disabilities, autistic people and other key stakeholders
2. Test the safety and feasibility of the AI chatbot through a mixed-methods single-arm feasibility study
3. Use the findings to develop a joint protocol and funding application for a subsequent feasibility RCT examining implementation and other feasibility questions before a future definitive RCT</studyHypothesis>
      <plainEnglishSummary>Background and study aims
People with learning (also called intellectual) disability and autistic people have more health problems and die at least 15 years younger than the rest of the population. To improve their health outcomes, we need to know what treatments work for them. This is usually done through clinical trials. However, we know that up to 90% of clinical trials, where people are allocated to either receive or not receive a treatment by chance (called randomisation) do not include people with learning disability or autism. This means we cannot be sure that treatments tested in people without learning disability or autism, will be appropriate for them.  

Aims of this research: Improve understanding of clinical trial information and support informed decision-making about research participation among people with intellectual disabilities (ID) and autistic people. We aim to do this by developing an artificial intelligence (AI) chatbot to explain research studies in a clear and accessible way and answer people’s questions. 

Who can participate?
Adults with intellectual disability or autistic adults

What does the study involve?
We will speak to people with learning disability, autistic people, their carers and researchers about using an AI chatbot to improve understanding of clinical trials and help them to decide to take part. We will use this information to design and improve the AI chatbot.  We will then test the AI chatbot in a small study. Around 10 people with learning disability and 10 autistic people will use the chatbot to learn about a clinical trial. We will record and analyse data from these interactions. We will also ask participants what they thought about it. We will ask clinical trial experts to use the AI chatbot and give their feedback. We will use what we have learnt to further improve the AI chatbot. 

What are the possible benefits and risks of participating?
No risks to participating in this study except for the person does not enjoying or getting bored by the AI chatbot. No specific benefits except that the person learns about what AI chatbots can do and how to operate them. 

Where is the study run from?
University College London (UK).

When is the study starting and how long is it expected to run for?
July 2026 to June 2028.

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK). 

Who is the main contact? 
Bhathika Perera, b.perera@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="e14ada1e-da95-4a97-8c59-e4fb5476a3b4">
	  <variable>Acceptability (≥70% of participants with neurodevelopmental disorders report that the chatbot helped them understand the study)</variable>
	  <method>Likert scale developed by the research team that is suitable for people with intellectual disability</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="61930051-c3f2-4756-925d-34a9f4728d75">
	  <variable>Adherence (≥70% of participants complete the chatbot interaction without abandoning the process)</variable>
	  <method>Likert scale developed by the research team that is suitable for people with intellectual disability</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="99c07e7b-65ea-4e0d-8b4f-ebf422d3c4f8">
	  <variable>Safety (no serious safeguarding events or misleading advice judged to pose significant risk, and all identified issues can be resolved through iterative refinement)</variable>
	  <method>the records of AI chatbot and interviews with participants</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="4c5e02d9-4694-4cc2-8245-c9e294b6c5ce">
	  <variable>Implementation feasibility (the majority (&gt;70%) of research staff indicate that the chatbot could be integrated into recruitment workflows with acceptable operational burden)</variable>
	  <method>Likert scale developed by the research team</method>
	  <timepoints>the end of using the AI chatbot</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="9b07a0da-aaf8-4aa2-abc5-03686a4e24bd" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60674326</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 516970</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="1ff91ede-9dc9-4b5e-90a1-3e06254f1888" numberType="nihr" canonicalSecondaryNumber="NIHR516970">516970</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>N/A: single arm study</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Device feasibility</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2028-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6193678f-332d-41e8-91a8-44efb74325a3">
	  <name>University College London division of psychiatry</name>
	  <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W1T 7NF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>Adults with intellectual disability and autistic adults, with carers where appropriate who are able to consent to participate in the study. This study registration is for the UK arm of the study as this study is also replicated in South Korea.</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment>20</totalFinalEnrolment>
      <exclusion>1. Any clinical, communication, safeguarding or other circumstance in which the research team judges that participation cannot be conducted safely despite reasonable adjustments
2. Cannot provide informed consent</exclusion>
      <recruitmentStart>2026-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Increase understanding and recruitment of people with intellectual disability or autistic people into clinical trials using an AI chatbot</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Single-arm mixed-methods feasibility study will evaluate use of the AI chatbot and inform iterative refinement.

This feasibility study aims to assess the feasibility of using an AI chatbot to help research participants learn about a study and decide whether to participate. So, the study Intervention is the use the AI chatbot. The duration of the intervention is the duration that each participant uses the AI chatbot. We estimate this to vary from 10 min up to 20 min. We will be monitoring this as part of the feasibility study. There is no follow-up once the participant completes the intervention.</description>
	<interventionType>Device</interventionType>
	<phase>Not Applicable</phase>
	<drugNames>AI chatbot</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>a5aed1df-e678-4223-9003-e52853961249</funderId>
      <contactId>2d8ca35e-d339-4907-a625-78c7dc275473</contactId>
      <contactId>4d45caa2-5bdf-413d-9dcb-07168b515585</contactId>
      <sponsorId>50f32064-83a5-4b54-9d39-70f4bbbb1633</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="2d8ca35e-d339-4907-a625-78c7dc275473">
    <title>Dr</title>
    <forename>Bhathika</forename>
    <surname>Perera</surname>
    <orcid>https://orcid.org/0000-0001-9316-9312</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7504 4186</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.perera@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4d45caa2-5bdf-413d-9dcb-07168b515585">
    <title>Miss</title>
    <forename>Elle</forename>
    <surname>Kim</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>4th Floor, Wings A and B, Maple House, 149 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 20 7504 4186</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ensue.kim.20@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="50f32064-83a5-4b54-9d39-70f4bbbb1633">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="a5aed1df-e678-4223-9003-e52853961249">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-10T17:09:47.4175482Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN16201377" publicIdentifierDateAssigned="2026-11-10T17:45:16.966895Z">
    <isrctn dateAssigned="2026-11-10T17:45:16.966895Z">16201377</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of reducing appearance related behaviours on body dysmorphic symptoms in university students at risk of body dysmorphic disorder</title>
      <scientificTitle>Effects of reducing appearance related behaviours on body dysmorphic symptoms in university students at risk of body dysmorphic disorder: a randomised controlled trial</scientificTitle>
      <acronym>REFLECT</acronym>
      <studyHypothesis>1. To evaluate the efficacy of the REFLECT intervention compared to an active control by estimating between group effect size difference on body dysmorphic symptoms at 2 weeks. The effect on secondary outcomes, including depressive and anxiety symptoms, will also be examined. 
2. To evaluate feasibility by calculating rates of recruitment and retention to the REFLECT intervention and the control condition
3. To evaluate the acceptability of the REFLECT intervention and the control condition by measuring acceptability and exploring participants experiences of the intervention procedures
4. To evaluate the safety of the REFLECT intervention and the control condition by calculating between group differences in negative effects</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Body dysmorphic disorder (BDD) is a mental health condition in which people worry a great deal about perceived flaws in their appearance and often feel very anxious and ashamed. BDD usually starts when people are teenagers and young adults. Without treatment, it can seriously affect people's lives. People with BDD are more likely to struggle in education and are at higher risk of suicide compared to people without the condition. 
There are effective treatments for BDD, but very few people receive treatment when they need it. We urgently need to develop interventions to help people earlier, before they develop BDD. 
This study aims to test an early intervention strategy for university students who are worried about their appearance, and whose worries are starting to get in the way of their lives. The intervention is based on a treatment already known to work for BDD (namely Cognitive Behavioural Therapy for BDD); it involves a brief 5-minute psycho-educational video, a brief therapeutic technique to practice daily, and daily text reminders. We aim to find out whether the intervention is better at reducing symptoms of BDD compared to an similar control condition.

Who can participate?
People can take part if they: 
1. Aged 18 years or older (there is no upper age limit)
2. Are registered UCL students
3. Have elevated but subclinical symptoms of BDD (this means they are unlikely to have BDD but their symptoms are still impairing)
4. Have not started or changed medication for a mental health condition in the past 6 weeks

What does the study involve?
Participants will first complete some questionnaires which assess whether they are eligible to be take part in the study. Then, they will be randomly assigned to either the intervention or the control condition. The group assigned to the intervention will watch a brief (about 5 minutes) video about the role of appearance related behaviours in maintaining appearance related concerns, are given a brief therapeutic technique to practice daily for 4 weeks and are sent text reminders every day for 4 weeks. Participants assigned to the control condition will also watch a brief video about the role of sleep in appearance anxiety, are given a brief therapeutic technique to practice daily for four weeks and are then sent text reminders every day for 4 weeks, as with the intervention condition. Each week both groups will be asked to complete a brief set of questionnaires. This will allow researchers to assess changes in BDD symptoms, and other mental health symptoms, and whether the participants in the intervention condition report greater improvement in BDD symptoms after 2 weeks compared to the control condition.
We are also interested to see whether the intervention and control are feasible (based on the number of participants recruited and retained in the study), acceptable to participants and are not associated with harmful effects. 

What are the possible benefits and risks of participating?
Participants may benefit from taking part if the intervention helps them feel less BDD symptoms, but, this cannot be guaranteed. Any participant who completes all data collection will be entered into a prize draw for £200. 
Some participants may find part of the intervention or control condition uncomfortable because it involves changing behaviours, which could lead to temporary feelings of anxiety or discomfort. 

Where is the study run from?
University College London (UCL) (UK)

When is the study starting and how long is it expected to run for?
November 2026 to December 2027

Who is funding the study?
UCL Grand Challenge for Mental Health and Wellbeing (UK)

Who is the main contact?
Prof. Georgina Krebs, g.krebs@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="804ec403-9d62-47e7-8fdd-219ce9719fd9">
	  <variable>Body dysmorphic disorder symptoms</variable>
	  <method>the Body Image Questionnaire (BIQ) (self-report)</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="6105242c-d3cd-4aa7-9340-0e4b7875a760">
	  <variable>Body dysmorphic disorder symptoms</variable>
	  <method>the Body Image Questionnaire (BIQ) (self-report)</method>
	  <timepoints>4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="83866952-d3d2-4117-aba5-278293e91ab2">
	  <variable>Anxiety symptoms</variable>
	  <method>Generalized Anxiety Disorder-7 (GAD-7) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="917551e5-897c-4763-aff0-697478581437">
	  <variable>Social anxiety symptoms</variable>
	  <method>the Mini-Social Phobia Inventory (Mini-SPIN) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2507c79d-0d94-4e1a-abde-de5ef42212b7">
	  <variable>Eating disorder symptoms</variable>
	  <method>the Eating Disorder Examination-Questionnaire (EDE-Q) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9161edaf-024b-4f47-b4c4-05d9591ccc65">
	  <variable>Depression symptoms</variable>
	  <method>the Patient Health Questionnaire-8 (PHQ-8) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8e2797e6-c933-424e-a414-97831cf34bdb">
	  <variable>Functioning</variable>
	  <method>the Work and Social Adjustment Scale (WSAS) (self-report)</method>
	  <timepoints>2 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9ac95ce6-7a74-483a-93f2-66e9e0f6aa64">
	  <variable>Recruitment into the trial</variable>
	  <method>the number of participants recruited</method>
	  <timepoints>each month</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="08fa3e14-b34d-4b4b-961d-37599768028a">
	  <variable>Retention</variable>
	  <method>the proportion of participants recruited who remain in the trial</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="508183f9-e217-4e62-9420-2a5b0d4b83ac">
	  <variable>Acceptability of the intervention and control conditions</variable>
	  <method>the Theoretical Framework for Acceptability (TFA) measure (self-report)</method>
	  <timepoints>2 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="fee8629e-7441-414f-8cdc-efed9ca1926b">
	  <variable>Effects of the intervention and control conditions</variable>
	  <method>an open text question and the Negative Effects Questionnaire (self-report)</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="6a004a22-74dd-4bb1-895b-249249196091">
	  <variable>Appearance related behaviours (intervention condition only)</variable>
	  <method>the self-report assessment of Appearance Related Safety Behaviours</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5f553a66-b35e-4b83-bf25-4c9e5e485030">
	  <variable>Sleep hygiene (control condition only)</variable>
	  <method>the Sleep Hygiene Index (self-report)</method>
	  <timepoints>1 week, 2 weeks, 3 weeks and 4 weeks post randomisation</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="a9b4dc14-efd7-4b8e-9e20-71a89e76303b" approvalStatus="approved" statusDate="2026-07-07T00:00:00.000Z">
	  <committeeName>UCL Life and Medical Sciences Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>University College London, Gower Street</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>WC1E 6BT</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>3666</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16201377</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber/>
      <secondaryNumbers/>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9c9d1344-acc5-48d8-8fc6-3e1fa28b455d">
	  <name>UCL Department of Clinical, Educational and Health Psychology</name>
	  <address>1-19 Torrington Place</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>WC1H 7HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Aged 18 years and over (there is no upper age limit)
2. Score between 20 and 39 on the Body Image Questionnaire (BIQ)
3. Be a UCL-registered student</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="110.0">110 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>190</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. BIQ score of less than 20 or 40 and above
2. Not be taking any new or have changed medications for a mental health condition within the previous 6 weeks</exclusion>
      <recruitmentStart>2026-11-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Body dysmorphic symptoms in university students at risk of body dysmorphic disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants will comprise of university students who report elevated but subthreshold body dysmorphic disorder symptoms as assessed by the Body Image Questionnaire (BIQ). Participants will be recruited from a community sample in University College London using physical adverts, digital advertising on platforms including the UCL learning management system - Moodle, and student mailing lists for selected departments within each faculty of the university. 

All participants will be recruited into the trial following a screening study where baseline measures are collected. The design of this screening study was informed by three co-design workshops (n = 8 to 10 UCL students each) held in October and December 2025 and January 2026. These workshops aimed to elicit students’ views on their needs, preferences and potential solutions to improve recruitment and retention to the study and interventions.  

Physical and digital advertisements will include QR codes to enable participants to go directly to the screening study.  
Emails will include the link and digital advert, with both enabling the participant to go to the screening study. 
In the screening study, participants who score between 20-39 on the BIQ will be able to proceed to the participant information sheet for this randomised controlled trial. Branching logic within the REDCap system will enable this process. 

Participants who wish to take part in the study will complete the consent procedure online in the REDCap system to proceed to the trial. All participants will be provided with information about sources of mental health support at UCL, in the NHS and via charities. 

The random allocation of participants to either the intervention or control condition in a one-to-one ratio will be conducted within the REDCap system. The randomisation list will be generated in an Excel document by a researcher independent of the trial personnel and incorporated into the REDCap module by this researcher. This list will not be accessible to the trial personnel, reducing the risk of unblinding. 

The intervention and control allocation and measures will be concealed within REDCap, thereby ensuring the trial personnel are not unblinded to the intervention assignment. 

While participants cannot be blinded to their intervention allocation, the following efforts aim to reduce bias. The intervention and control conditions are similar in terms of credibility scores in a pilot study; credibility scores will be measured following allocation and following delivery of the therapeutic video. Both conditions follow the same structure in terms of activities, timing, form of the therapeutic instruction provided to each participant and the receipt of daily updates for a total of four calendar weeks following baseline. 

Due to the brief nature of the intervention, a procedure for emergency unblinding is not required. 

Both intervention and control conditions will be delivered digitally, whereby participants can access the brief (~5-minute) psychoeducational video and therapeutic instructions via the REDCap system. Both the intervention and control videos are as similar as possible in terms of length, text to read, structure, and style. In both the intervention and control condition, the video is followed by daily text reminders over the following four weeks. 

Intervention condition:
The intervention condition is informed by CBT for body dysmorphic disorder, which has demonstrated efficacy in reducing appearance-related behaviours and body dysmorphic disorder symptoms (Abdalla et al., 2026). The intervention is theory-based in that it draws on the hypothesised active ingredients from CBT for BDD (Patel &amp; Cougle, 2024; Wilhelm et al., 2013). A putative active ingredient is exposure and response prevention (ERP), which involves reducing appearance-related behaviours. These behaviours are a criterion for the diagnosis of BDD and are thought to maintain appearance preoccupation (Patel &amp; Cougle, 2024; Wilhelm et al., 2013). 

The intervention condition is also informed by pilot data and evidence from a randomised controlled trial (Patel &amp; Cougle, 2024). A single-arm pilot study of the intervention was conducted in July 2026, comprising n=29 participants recruited from Prolific. To approximate the age distribution of UCL students, participants were included if aged between 18 and 30 years old. Participants followed the intervention activities of the planned trial: i) viewed a psychoeducational video and therapeutic instructions and ii) were sent daily text reminders for two weeks. 

The intervention will be completed by participants either on a computer, tablet or a mobile phone. Within the REDCap platform, participants will be able to view an approximately five-minute psychoeducational video about the role appearance-related behaviours play in maintaining body dysmorphic disorder symptoms. The video concludes with the therapeutic instructions: 1) to identify appearance-related behaviours and 2) to stop appearance-related behaviours over the following four weeks. After the video, a short four-sentence summary of the key points of the video and the task is shown, and participants are asked to take a screenshot of the summary. Participants then receive daily automated text reminders of the task via REDCap for a total of four calendar weeks. 

Control condition:
The active control condition is based upon evidence that sleep hygiene interventions are a transdiagnostic target for reducing internalising symptoms (Freeman et al., 2017). The active control condition is based on evidence that sleep problems and body dysmorphic disorder symptoms commonly co-occur (Sevilla-Cermeño et al., 2020). Moreover, there is preliminary observational evidence that insomnia has a negative impact on treatment outcomes among individuals with BDD (Sevilla-Cermeño et al., 2020).

This active control condition follows the same structure as the intervention condition. Participants view an approximately five-minute video about how difficulties sleeping can reduce capacity to respond to body dysmorphic disorder symptoms and can intensify distress. The video has a two-step task: 1) to identify areas of sleep hygiene participants can improve, 2) to improve these behaviours. As with the intervention condition, participants will be provided with a short summary of the key points and the task. The schedule of reminders follows the exact same structure as the intervention condition.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (e.g., GitHub).</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Stored in publicly available repository</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="503fa464-5712-47b6-957f-b281f0b3edf5" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-10-16T00:00:00.000Z" dateUploaded="2026-11-10T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="141f9977-43c0-4758-9eb7-2d007af45d61" originalFilename="50630_Protocol_V1_16Oct2026.pdf" downloadFilename="50630_Protocol_V1_16Oct2026.pdf" version="1" mimeType="application/pdf" length="396870" md5sum="8f448f14d7e736a140c3a38b71c9ceef"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>afa6548c-b39d-43a1-84ba-eb5af9ec817d</funderId>
      <contactId>cc8b2f73-7dec-4728-9ddc-7dec7a438f69</contactId>
      <sponsorId>ae9bfcc6-3eca-43c5-9fd5-3dacb434d327</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/141f9977-43c0-4758-9eb7-2d007af45d61/50630">
	<description>Protocol file</description>
	<name>50630_Protocol_V1_16Oct2026.pdf</name>
	<id>141f9977-43c0-4758-9eb7-2d007af45d61</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>396870</length>
	<md5sum>8f448f14d7e736a140c3a38b71c9ceef</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="cc8b2f73-7dec-4728-9ddc-7dec7a438f69">
    <title>Prof</title>
    <forename>Georgina</forename>
    <surname>Krebs</surname>
    <orcid>https://orcid.org/0000-0002-5353-5645</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>1-19 Torrington Place, University College London</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1E 7HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7679 1897</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.krebs@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="ae9bfcc6-3eca-43c5-9fd5-3dacb434d327">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="afa6548c-b39d-43a1-84ba-eb5af9ec817d">
    <name>University College London</name>
    <fundRef>http://dx.doi.org/10.13039/501100000765</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-02T14:04:17.737994821Z" version="12" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN24285790" publicIdentifierDateAssigned="2026-11-02T14:04:17.861285Z">
    <isrctn dateAssigned="2026-11-02T14:04:17.861285Z">24285790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Precision blood transfusion</title>
      <scientificTitle>​​​​​​​​A single centred feasibility study to evaluate and compare the implementation of an antigen-prioritising algorithm with standard care to arrange units for blood transfusion prior to selection by staff at NHS Blood and Transplant (NHSBT)</scientificTitle>
      <acronym>Haem-Match Feasibility Study</acronym>
      <studyHypothesis>Primary objective:
To evaluate the implementation of a principally antigen-prioritised algorithm (bloodMatcher) vs. the current principally age-prioritised algorithm used to arrange units for blood transfusion prior to selection by staff at NHSBT at a single SHU.

Secondary objective:
To compare the degree of matching of blood groups achieved by bloodMatcher with that achieved by its present equivalent (standard of care), which organises units principally according to age.

Tertiary objective:
To inform the design of future multicentred studies of bloodMatcher, including the capabilities for electronic capture of relevant outcome and transfusion data.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
People with sickle cell disorder often need regular blood transfusions. Although blood is matched for some important blood groups, some patients still develop antibodies against donated blood. This can make future transfusions more difficult and increase the risk of serious transfusion reactions.

Researchers have developed a computer-based tool called bloodMatcher. This tool helps NHS Blood and Transplant (NHSBT) staff select donor blood by looking at a wider range of blood group information. The aim is to improve how closely donated blood matches each patient. Better matching may reduce transfusion-related complications and help make the best use of rare blood units. This study will assess whether bloodMatcher can be used safely and effectively within routine NHSBT practice before larger studies are carried out.

Who can participate?
People may be able to take part if they:
1. Are aged 16 years or older
2. Have sickle cell disorder of any type
3. Have been receiving regular exchange blood transfusions for at least three consecutive transfusion episodes
4. Has had a genotype submitted for analysis on the axiom array
5. Are willing and able to give written informed consent
People cannot take part if they are difficult to transfuse because of certain previous transfusion complications, have had significant problems attending their transfusion appointments, or are currently pregnant or planning a pregnancy.

What does the study involve?
Around 40 people with sickle cell disorder who already receive regular exchange blood transfusions will be invited to join the study.
Participants will continue to receive their usual care from their normal clinical team. There will be no extra hospital visits, and no new medicines or treatments will be given.
Researchers will compare information from three previous transfusion episodes that used the standard blood selection process with three study transfusions that use information from the bloodMatcher system. Before each transfusion, participants will have their usual blood tests. Women of childbearing age will also have a pregnancy test.
The main difference during the study is that bloodMatcher will help NHSBT staff choose suitable donor blood units. Experienced transfusion scientists will review all suggested blood units to ensure they are safe and meet national standards. If a suggested unit is not suitable, the standard blood selection process will be used instead.
Any transfusion reactions or delays will be recorded. After the third study transfusion, the research team will review the collected information. Participants can withdraw from the study at any time without it affecting their medical care.
What are the possible benefits and risks of participating?
Participants may not receive a direct benefit from taking part. However, bloodMatcher may help achieve closer blood group matching between donors and recipients. This could potentially reduce the risk of transfusion-related complications.
The risks are expected to be low because participants will continue to receive standard transfusion care. The blood units selected using bloodMatcher will undergo the same safety checks as routine transfusions, with additional review by senior transfusion scientists. If any concerns arise, the standard blood selection process will be used.

Where is the study run from?
NHS Blood and Transplant (UK)

When is the study starting and how long is it expected to run for?
July 2026 to July 2027

Who is funding the study?
The study is funded by NHS Blood and Transplant, the National Institute for Health and Care Research (NIHR), and the University College London Hospitals Biomedical Research Centre.

Who is the main contact?
Uclh.haem-match@nhs.net</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="e346f24c-c43d-40d7-a0c1-c46073f17b92">
	  <variable>Approval or rejection by the Haem-Match Multidisciplinary Team (MDT) of each blood unit recommended by bloodMatcher, including the reason for any rejection (categorical)</variable>
	  <method>review of recorded Haem-Match MDT decisions for each recommended unit</method>
	  <timepoints>the MDT review of each blood order, before transfusion</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="50d82396-1b2b-44e9-9388-0445eebee6fd">
	  <variable>Whether bloodMatcher-selected units are available when required for each blood order, and whether these units are transfused or standard practice is used to select alternative, non-algorithm-selected units</variable>
	  <method>review of blood bank records, bloodMatcher recommendations and transfusion records to establish unit availability, identify the units actually transfused and record the reason for reverting to standard practice, where applicable</method>
	  <timepoints>blood unit selection and at each transfusion</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Whether an antigen-positive blood unit is transfused to an antigen-negative recipient (binary), assessed for each transfused unit and each blood group antigen evaluated measured using comparison of donor-unit and recipient antigen profiles recorded in laboratory/blood bank records, linked to the record of units actually transfused at each transfusion
2. Whether an antigen-negative blood unit is transfused to an antigen-positive recipient (binary), assessed for each transfused unit and each blood group antigen evaluated measured using comparison of donor-unit and recipient antigen profiles recorded in laboratory/blood bank records, linked to the record of units actually transfused at each transfusion
3. Key changes to study procedures, bloodMatcher implementation and transfusion workflows required to enable a future multicentre study measured using review of study findings and documented operational issues to identify and describe the changes require at the end of the study</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="d5486c8f-ed68-4134-970f-694c9b60990c" approvalStatus="approved" statusDate="2026-03-16T00:00:00.000Z">
	  <committeeName>West Midlands – South Birmingham Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/WM/0011</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24285790</doi>
      <eudraCTNumber/>
      <irasNumber>354482</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 71019, AI_AWARD02331</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="0f9da68f-972a-4638-add1-9512625e8f8d" numberType="iras" canonicalSecondaryNumber="IRAS354482">354482</secondaryNumber>
	<secondaryNumber id="a984827f-ceca-48b7-9275-4671becb4a68" numberType="cpms" canonicalSecondaryNumber="CPMS71019">71019</secondaryNumber>
	<secondaryNumber id="b2064c72-a3cb-4bde-a10b-84d2285327c6" numberType="Grant code">AI_AWARD02331</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>N/A: single arm study</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Basic science</purpose>
	  <purpose>Device feasibility</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2027-07-09T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5c990188-5306-4e39-8c2c-4427af11fb97">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>RRV00@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. 16 years or older 
2. Sickle Cell Disorder (any genotype) on a regular EBT programme for at least three contiguous episodes
3. Has a red cell genotype submitted for analysis on the Axiom array 
4. Is willing to be approached for NIHR BioResource Research Tissue Bank Improving Health Outcomes (IBHO) study (REC22/EE/0230)
5. Willing and able to provide written informed consent</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="16.0">16 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="120.0">120 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment>40</totalFinalEnrolment>
      <exclusion>1. Difficult to transfuse - defined as needing NHSBT Red Cell Immunohaematology (RCI) support for sourcing appropriate units or crossmatching units for transfusion OR episode of hyperhaemolysis in the past OR Delayed haemolytic transfusion reaction in last 4 months
2. Previous poor concordance or irregularity with transfusion regimen – defined as repeated changing appointment dates with little notice,or non-timely attendance for group and screen or for transfusion episodes (at discretion of PI)
3. Current pregnancy or planning to become pregnant (a known risk factor for alloimmunisation)</exclusion>
      <recruitmentStart>2026-07-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-10-09T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemolytic anaemias</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a single-site retrospective-prospective feasibility study using an algorithm called bloodMatcher, which arranges units prior to selection by NHS Blood and Transplant (NHSBT) staff principally according to blood group matching and compares it with the current algorithm, which principally arranges units according to age. The system aims to match donated blood to people with sickle cell disorder more closely by using detailed blood group information, rather than the current system, which mainly selects blood by age. Better matching may reduce the chance of reactions and other complications for patients and, at a system level, reduce the allocation of rare units to people who do not need them, preserving this valuable resource for those who do.

Around 40 adults with sickle cell disorder who already receive regular exchange blood transfusions will be invited to take part. We will compare data from three previous transfusion episodes using the current algorithm with data from three study transfusions in which bloodMatcher is incorporated. Taking part will not change participants' usual treatment, and their clinical care will continue to be coordinated by the same clinical team. They will be approached by the research team, provided with information about the study, and asked to give written consent if they wish to participate. Women of childbearing potential will undergo a pregnancy test.

Before each transfusion, participants will have the usual blood tests. The only difference is that the BloodMatcher algorithm will help NHSBT staff choose donor blood units primarily based on their best match for the recipient instead of the current storage age-based system. Senior transfusion scientists will review each suggested unit to ensure it is safe and meets national standards, providing an additional layer of oversight within the study protocol. Several other established checking procedures performed by NHSBT Hospital Services staff, as well as laboratory and nursing staff prior to transfusion administration, will remain unchanged. If a suggested blood unit is not suitable, the current algorithm will be used instead.

Transfusions will take place in the usual way, and any reactions or delays will be recorded. After the third study transfusion, the research team will review the data. There are no additional hospital visits, no new drugs or treatments, and participants may withdraw from the study at any time without affecting their clinical care.</description>
	<interventionType>Device</interventionType>
	<phase>Not Applicable</phase>
	<drugNames>BloodMatcher algorithm</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4b09ce73-ae39-4bf5-9e69-04044ecc2777" outputType="pis" artefactType="LocalFile" dateCreated="2020-03-26T00:00:00.000Z" dateUploaded="2026-07-30T00:00:00.000Z" peerReviewed="false" patientFacing="true" createdBy="">
	<localFile fileId="a023c44d-d37d-49dd-b0be-d88dbbafb537" originalFilename="49796 26Mar20_V1_Haem-Match_Participant_Information_Sheet.pdf" downloadFilename="49796 26Mar20_V1_Haem-Match_Participant_Information_Sheet.pdf" version="1" mimeType="application/pdf" length="338162" md5sum="f4d58886973da58c3ef664cfaf3d7043"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="dafdad21-4fa8-4f27-b45e-2a363d94f4b5" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-01-29T00:00:00.000Z" dateUploaded="2026-07-30T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="9b7e4e5f-2fc4-45be-80e9-9032206ef612" originalFilename="49796 29Jan2026_IRAS354482_Haem-Match_Protocol_V1_.pdf" downloadFilename="49796 29Jan2026_IRAS354482_Haem-Match_Protocol_V1_.pdf" version="1" mimeType="application/pdf" length="1203122" md5sum="fc4c5edb95966fcdc36f21ddec00b966"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>8cc78910-363b-4305-ae56-2e377b80bbb3</funderId>
      <funderId>e604c9df-2265-4088-95d7-020ff86cfe9a</funderId>
      <funderId>9810eb22-f3cd-4248-bb9c-76f3b1bd8301</funderId>
      <contactId>51e74d31-4605-4462-9e9c-ad7b13034c02</contactId>
      <contactId>a981817f-7277-49c8-bd7e-b2821f14ddc4</contactId>
      <sponsorId>4c6932ff-6406-4d8f-a0bf-199549b128f0</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/a023c44d-d37d-49dd-b0be-d88dbbafb537/49796">
	<description>Participant information sheet</description>
	<name>49796 26Mar20_V1_Haem-Match_Participant_Information_Sheet.pdf</name>
	<id>a023c44d-d37d-49dd-b0be-d88dbbafb537</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>338162</length>
	<md5sum>f4d58886973da58c3ef664cfaf3d7043</md5sum>
      </attachedFile>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/9b7e4e5f-2fc4-45be-80e9-9032206ef612/49796">
	<description>Protocol file</description>
	<name>49796 29Jan2026_IRAS354482_Haem-Match_Protocol_V1_.pdf</name>
	<id>9b7e4e5f-2fc4-45be-80e9-9032206ef612</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1203122</length>
	<md5sum>fc4c5edb95966fcdc36f21ddec00b966</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="51e74d31-4605-4462-9e9c-ad7b13034c02">
    <title>Dr</title>
    <forename>Sara</forename>
    <surname>Trompeter</surname>
    <orcid>https://orcid.org/0000-0002-7099-8449</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Colindale Blood Donor Centre
6 Lingard Avenue</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>NW9 5BG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">uclh.haem-match@nhs.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="a981817f-7277-49c8-bd7e-b2821f14ddc4">
    <title>Dr</title>
    <forename>Nicholas</forename>
    <surname>Gleadall</surname>
    <orcid>https://orcid.org/0000-0002-1132-1059</orcid>
    <contactTypes>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>NHS Blood and Transplant, Addenbrooke’s Hospital, Long Road</address>
      <city>Cambridge</city>
      <state/>
      <country>United Kingdom</country>
      <zip>CB2 0PT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">uclh.haem-match@nhs.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="4c6932ff-6406-4d8f-a0bf-199549b128f0">
    <organisation>NHS Blood and Transplant</organisation>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <rorId>https://ror.org/0227qpa16</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="8cc78910-363b-4305-ae56-2e377b80bbb3">
    <name>NHS Blood and Transplant</name>
    <fundRef>http://dx.doi.org/10.13039/100009033</fundRef>
  </funder>
  <funder id="e604c9df-2265-4088-95d7-020ff86cfe9a">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
  <funder id="9810eb22-f3cd-4248-bb9c-76f3b1bd8301">
    <name>University College London Hospitals Biomedical Research Centre</name>
    <fundRef>http://dx.doi.org/10.13039/501100012621</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-11-02T10:22:07.620566382Z" version="10" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN16699902" publicIdentifierDateAssigned="2026-11-02T10:22:07.749798Z">
    <isrctn dateAssigned="2026-11-02T10:22:07.749798Z">16699902</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical study investigating whether it is safe to give children with newly diagnosed pontine diffuse midline glioma a drug called MTX110 using a device that helps deliver the drug directly to the tumour in the brain</title>
      <scientificTitle>A safety and feasibility study to investigate administration of intratumoral MTX110 via convection-enhanced delivery in children with newly diagnosed pontine diffuse midline glioma</scientificTitle>
      <acronym>DELIVERY</acronym>
      <studyHypothesis>Primary objectives:
1. To assess the feasibility of implantation of the NDDS device and delivery of infusion
2. To assess the safety, toxicity and tolerability of MTX110 convection-enhanced delivery (CED) and the NDDS device

Secondary objectives:
1. To assess the efficacy of the CED treatment
2. To assess the accuracy of implantation of the NDDS device
3. To assess port stability
4. To assess the patency of the NDDS device
5. To assess radiological (MRI) treatment response using the Response Assessment in Paediatric Neuro-Oncology (RAPNO) scale
6. To assess the quality of life of participants</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
Pontine diffuse midline glioma (DMG) is an extremely aggressive childhood brain tumour and is responsible for most brain tumour-related deaths in children. Most children survive for less than 1 year after diagnosis, and only around 10% survive beyond 2 years. These tumours develop deep within the brain, making surgical removal unsafe in most cases.
The current standard treatment is radiotherapy, which aims to shrink the tumour and relieve symptoms. However, radiotherapy is not curative and usually extends survival by only a few months. Standard chemotherapy has not been effective for DMG because the brain’s natural protective barriers, the blood–brain barrier (BBB) and blood–tumour barrier (BTB), prevent many drugs from reaching the tumour in sufficient amounts.
Previous studies have shown that it is feasible and safe to deliver drugs directly into the tumour, using an implantable device called the NeuroChase Drug Delivery System (NDDS). This device uses four very thin tubes, called catheters, which are carefully placed into the brain using detailed imaging to ensure accuracy. The tubes are connected to a ’port’ that sits on the skin surface. 
MTX110 is a new medicine that has shown promising results in an early clinical trial for children with DMG in the USA. In that study, doctors were able to find a dose that was both safe and potentially improved treatment, with children who received MTX110 directly into the tumour on average living longer than would usually be expected.
This study will investigate whether repeated doses of MTX110 delivered directly into the tumour after radiotherapy are safe and whether this approach may help children with newly diagnosed pontine DMG live longer. 

Who can participate? 
Patients age 3 to 16 years with DMG

What does the study involve? 
Participants will receive MTX110 infusions every 2–3 weeks until tumour progression.

What are the possible benefits and risks of participating? 
Not provided at time of registration 

Where is the study run from? 
Cancer Research UK &amp; UCL Cancer Trials Centre (UK)

When is the study starting and how long is it expected to run for? 
January 2027 to September 2032

Who is funding the study? 
Medical Research Council (UK)

Who is the main contact?
1. DELIVERY Trial Manager, ctc.DELIVERY@ucl.ac.uk
2. Dr Elwira Szychot, elwira.szychot@gosh.nhs.uk

Plain English summary under review with external organisation</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>1. Feasibility of implantation of the NDDS device and delivery of infusion evaluated by:
1.1. The number of participants provided NDDS implantation
1.2. The number of infusions for each participant
1.3. Any changes needed to the delivery
Measured from device implantation to end of study treatment
2. Safety and toxicity of MTX110 CED and the NDDS device evaluated by:
2.1. The number of participants experiencing a Dose Limiting Toxicity (DLT)
2.2. The type and grade of adverse events (CTCAE v5) by cycle
2.3. The duration of each type of adverse event, especially grade 3-4
2.4. The length of hospital stay due to adverse events
Measured from device implantation to end of study treatment
3. Tolerability, defined as the time participants spend adverse event free or clinical grade 3-4 adverse event free, measured continuously throughout treatment</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Progression-free survival measured using time from date of diagnosis until date of tumour progression or death
2. Time to progression, both local and distant will be considered separately if appropriate, measured using time from date of diagnosis until date of radiological progression
3. Overall survival measured using time from date of diagnosis until date of death
4. Accuracy of implantation of NDDS device measured using the difference between the planned and actual position of each catheter at the end of study treatment 
5. Port stability measured using the number of participants with an unstable port at the end of study treatment
6. Patency of the NDDS device measured using the incidence of channel blockage that cannot be rectified at the end of study treatment incidence of channel blockage which cannot be rectified
7. Radiological (MRI) treatment response measured using the Response Assessment in Paediatric Neuro-Oncology (RAPNO) scale after every three infusions 
8. Quality of life measured using PedsQL at baseline, prior to cycle 1, cycle 4, cycle 8 and every 3 months after discontinuation of study treatment or disease progression</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="aac0c290-27a7-4694-95a5-3e913186f7d9" approvalStatus="submitted" statusDate="2026-08-11T00:00:00.000Z">
	  <committeeName>To be confirmed</committeeName>
	  <contactDetails>
	    <address>-</address>
	    <city>-</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>-</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/NW/0243</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16699902</doi>
      <eudraCTNumber/>
      <irasNumber>1009032</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>UCL163249</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="6ad84b08-060d-433e-897e-689f3d1f6899" numberType="iras" canonicalSecondaryNumber="IRAS1009032">1009032</secondaryNumber>
	<secondaryNumber id="258f445e-6869-4931-929c-76d84c707db4" numberType="Sponsor's protocol code number">UCL163249</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>N/A: single arm study</allocation>
	<masking>Open (masking not used)</masking>
	<control>Uncontrolled</control>
	<assignment>Single</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	  <purpose>Safety</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Efficacy</trialType>
	<trialType>Safety</trialType>
	<trialType>Treatment</trialType>
	<trialType>Other</trialType>
      </trialTypes>
      <overallEndDate>2032-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="08f79d3c-36b3-41d6-89a7-fb1f6541727f">
	  <name>Great Ormond Street Hospital for Children</name>
	  <address>Great Ormond Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>WC1N 3JH</zip>
	  <rtsId>RAJ2E@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Age ≥3 and ≤16 years at the time of diagnosis
2. Biopsy proven new diagnosis of H3K27M altered diffuse midline glioma (DMG) confined to the pons
3. Radiological diagnosis of pontine DMG (DIPG) confirmed by magnetic resonance imaging (MRI), defined as tumours with a pontine location and diffuse involvement of at least 2/3 of the pons, based on diagnostic images before radiotherapy. 
4. No structural/anatomical changes cystic changes or hematoma obstructing the planned catheter trajectories identified on radiological images
5. Started focal radiotherapy by external beam to the brainstem as per local policy within 2-3 weeks from the time of diagnosis
6. Must be on a stable or decreasing dose of dexamethasone for at least 1 week prior to registration
7. Must be able to undergo MRI imaging with gadolinium based contrast administration (e.g., no ferrous-containing implants, no pacemakers etc) and a CT angiogram (with contrast) in order to facilitate surgical planning
8. No contraindications to neurosurgical implantation or general anaesthesia
9. Karnofsky Performance Status (age ≥ 10 years) or a Lansky Play Score of ≥50 assessed at diagnosis
10. Adequate renal function with glomerular filtration rate (GFR) ≥60 ml/min/1.73m2, based on a calculated method
11.	Adequate liver function:
11.1. Total bilirubin ≤2 × upper limit of normal (ULN) for age
11.2. Alanine aminotransferase (ALT) ≤2.5 × ULN for age 
12.	Adequate haematological function:
12.1. Haemoglobin ≥10 g/L (no transfusion within 7 days)
12.2. Peripheral absolute neutrophil count ≥1.5 x 10 9/L
12.3. Platelet count  ≥100 x 10 9/L (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to   registration)
12.4. Normal coagulation defined as normal international normalized ratio (INR) or per institutional guidelines
13.	Participant and/or parent/legal guardian able to understand, and willing to sign, written informed consent 
14. Willing and able to participate in all required evaluations and procedures in the study protocol
15.	Negative serum or urine pregnancy test for women of childbearing potential (WOCBP) 
16. Willing to comply with the contraceptive requirements of the study</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="years" value="3.0">3 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="16.0">16 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>9</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Radiological evidence of metastatic disease within the central nervous system (CNS) at diagnosis, including leptomeningeal or subarachnoid disseminated disease or other multifocal disease
2. Clinical and/or radiographic (MRI) progression of tumour following external beam radiation therapy
3. Unfavourable tumour morphology or the presence of a cavity or cysts that represent &gt;50% of cross-sectional areas of the pons that may lead to poor convection-enhanced delivery (CED) coverage of a relevant part of the tumour. These participants should be discussed with the TMG
4. MRI or clinical evidence of uncontrolled tumour mass effect. The assessment of mass effect should be made by the treating team including neurosurgical input prior to any planned CED treatment
5. Untreated symptomatic hydrocephalus determined by the treating clinician
6. Non-correctable bleeding disorder
7. Signs of impending herniation or an acute intratumoral haemorrhage
8. Previous chemotherapy, investigational agents, biologic therapy, or other tumour-directed therapy for treatment of the tumour. Note: Radiotherapy as per inclusion criteria 5 and treatment directed at preventing or controlling oedema e.g. steroids before, during or after radiotherapy is allowed
9. History of allergic reactions or hypersensitivity attributed to compounds of similar chemical composition or pharmacological class to MTX110
10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic heart failure, cardiac arrhythmia, or psychiatric illness/social situations, that could limit compliance with study requirements
11.	Systemic diseases which may be associated with unacceptable anaesthetic/operative risk
12.	History of seizures/epilepsy not well controlled on non-enzyme inducing anticonvulsant medication
13.	Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) or human immunodeficiency virus (HIV) antibody positive
14. A device associated or other MRI artifact that would preclude planning or placement of the catheter system
15. Participants who in the opinion of the Investigator are unsuitable to participate
16. Life expectancy &lt;12 weeks</exclusion>
      <recruitmentStart>2027-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2030-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Paediatric pontine diffuse midline glioma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following standard-of-care radiotherapy to the tumour, the Neurochase Drug Delivery System (investigational medical device) will be surgically implanted into the tumour before MTX110 (CTIMP) treatment begins. Participants will then receive MTX110 infusions on Days 1 and 2 of each treatment cycle via four catheters (two transfrontal and two transcerebellar), with an overnight interval between infusions. Treatment cycles will be repeated every 2–3 weeks until there is evidence of tumour progression. Trial treatment will be discontinued if participants experience unacceptable toxicity or tumour progression.</description>
	<interventionType>Drug/Device</interventionType>
	<phase>Phase I</phase>
	<drugNames>MTX110 (panobinostat), NeuroChase Drug Delivery System (NDDS)</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>64609f6f-0e5c-4eff-8548-8e82f4a0dae6</funderId>
      <contactId>d1048883-1557-4a94-b5c8-72627f851131</contactId>
      <contactId>6e3c1964-e670-4a3b-b19b-e55d191822c8</contactId>
      <sponsorId>571b8cf3-98fa-41a2-a94d-c71216bf1dde</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="d1048883-1557-4a94-b5c8-72627f851131">
    <title>None</title>
    <forename>DELIVERY</forename>
    <surname>Trial Manager</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>CRUK &amp; UCL Cancer Trials Centre, Maple House, 149 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 76799860</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ctc.DELIVERY@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="6e3c1964-e670-4a3b-b19b-e55d191822c8">
    <title>Dr</title>
    <forename>Elwira</forename>
    <surname>Szychot</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Great Ormond Street Hospital, Great Ormond Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1N 3JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">elwira.szychot@gosh.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="571b8cf3-98fa-41a2-a94d-c71216bf1dde">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="64609f6f-0e5c-4eff-8548-8e82f4a0dae6">
    <name>Medical Research Council</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-21T10:20:40.816985759Z" version="11" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN39538766" publicIdentifierDateAssigned="2026-10-21T10:20:40.930666Z">
    <isrctn dateAssigned="2026-10-21T10:20:40.930666Z">39538766</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>Hippocrates is a research trial which aims to help us understand  how the NHS can help people who need a major operation to recover better and more quickly after the operation</title>
      <scientificTitle>Health Inequalities in PerioPerative Outcomes – CReATing and Evaluating targeted Support interventions (HIPPOCRATES): a pilot multi-arm randomised controlled trial</scientificTitle>
      <acronym>HIPPOCRATES</acronym>
      <studyHypothesis>1. Deliver a pilot randomised trial using a multi-arm methodology to evaluate three co-designed interventions in patients undergoing elective major surgery from deprived and non-deprived socioeconomic groups
2. Evaluate the implementation (feasibility, acceptability and fidelity) of these interventions using mixed methods
3. Estimate the cost-effectiveness of the three interventions evaluated during the pilot RCT
4. Selection and refinement of the most promising intervention to move forward to large scale RCT based on the mixed methods evaluation</studyHypothesis>
      <plainEnglishSummary>Background and study aim
Every year more than 1.5 million people in the UK have major surgery, and more than 1 in 7 have a serious complication afterwards. People who live in poorer areas are more likely to have complications and to recover less well. This study is testing three types of support, designed together with patients from poorer areas, to find out whether they are practical, acceptable and good value for money. The results will then inform decisions on which intervention(s) should be tested in a larger trial, either alone or in combination with each other.

Who can participate? 
Adults aged 18 or over who are on the waiting list for a major operation (not heart or brain surgery) that usually needs at least 3 nights in hospital, with surgery expected to take place in 1 to 6 months.

What does the study involve? 
Participants are put by chance into one of four groups: 
1. Help to get fitter and healthier before surgery, covering exercise, diet, mental wellbeing and long-term health conditions
2. Financial and welfare support and advice and, if needed, additional support in the form of vouchers
3. A small wearable monitor and text-message check-ins after the operation to spot problems early
4. Usual NHS care

Everyone completes short questionnaires before surgery and at 1, 6 and 12 months afterwards. Some people will be invited to talk about their experience in an interview. Information is available in the five most common languages other than English and in other formats.

What are the possible benefits and risks of participating? 
Participants may recover better, but this cannot be guaranteed. The risks are small. Exercise is prescribed by trained staff, and people at higher risk exercise only under supervision. Completing questionnaires takes some time.

Where is the study run from?
The study is coordinated by University College London (UCL), through its Comprehensive Clinical Trials Unit, and will take place at approximately 12 NHS hospitals across England (UK), with the possibility of additional sites.

When is the study starting and how long is it expected to run for? 
Recruitment is expected to run from January 2027 for a minimum of one year. Each participant is followed up for 12 months after their operation. The trial team are seeking additional funding to evaluate new interventions, so it is possible that the duration of this pilot study will be extended. Completion is in October 2029.

Who is funding the study? 
National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research (UK).

Who is the main contact? 
HIPPOCRATES trial team, cctu.hippocrates@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="f9e763b9-5fea-42fe-88bc-a5a5dab4b8cc">
	  <variable>The total number of days a patient stays alive and outside of a hospital setting</variable>
	  <method>the Days Alive and Out of Hospital at 30 days post-surgery (DOAH30)</method>
	  <timepoints>30 days post-surgery</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="cc2a6011-52d8-4df8-90ce-55635615fe81">
	  <variable>Inpatient postoperative complications (Clavien-Dindo grading)</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="e7fc53e5-a598-4163-b4fe-15eae5264181">
	  <variable>Postoperative hospital length of stay (LOS) until medically fit for discharge</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="9b62a273-3474-45c1-9490-f3bc5bf42352">
	  <variable>Postoperative LOS (total on primary admission)</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="7d8c2ea2-dfb8-45a9-843e-16ffa00e6bcc">
	  <variable>Time between date of study recruitment/randomisation and date of surgery</variable>
	  <method>prospective data collection at trial location-level (research staff led)</method>
	  <timepoints>hospital discharge</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="1ae02003-667d-43ac-aaf4-3df651a2a9fa">
	  <variable>Health-related quality of life</variable>
	  <method>the EuroQol Five-Dimension Five-Level questionnaire (EQ-5D-5L)</method>
	  <timepoints>baseline, preoperatively, and 30 days, 6 months, and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ad17f4d4-e6a6-4a2c-a4c2-b8cc9d03a712">
	  <variable>Disability and functioning</variable>
	  <method>the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)</method>
	  <timepoints>baseline, preoperatively, and 6 months and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="79b1f0ca-3831-4766-9238-1cf08d71e270">
	  <variable>Anxiety and depression symptoms</variable>
	  <method>the Hospital Anxiety and Depression Scale (HADS)</method>
	  <timepoints>baseline, preoperatively, and 30 days postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="3e351e10-b267-4cf5-aa4a-ee3d19df236e">
	  <variable>Functional capacity</variable>
	  <method>the Duke Activity Status Index (DASI)</method>
	  <timepoints>baseline and preoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="eb7e331a-c79b-4e2e-b09d-002f982cf849">
	  <variable>Healthcare resource use</variable>
	  <method>the Resource Use Measure questionnaire</method>
	  <timepoints>baseline and 6 months and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="f7bef44f-5f66-4980-83f4-89a67988bb5a">
	  <variable>Decision regret</variable>
	  <method>the Decision Regret Scale</method>
	  <timepoints>30 days, 6 months, and 12 months postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="b6959778-cd86-42f4-a955-e2ef8145a227">
	  <variable>All-cause mortality</variable>
	  <method>linkage to NHS England Hospital Episode Statistics (HES) and/or Office for National Statistics (ONS) mortality records</method>
	  <timepoints>30 days, 90 days, and 1 year postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="67cb754c-7d30-45ed-a08e-d9e169890737">
	  <variable>Days alive and out of hospital</variable>
	  <method>linkage to NHS England HES and/or ONS mortality records</method>
	  <timepoints>30 days, 90 days, 180 days, and 1 year postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="ce1e1ea2-d25a-4858-b988-afc7c25f9820">
	  <variable>Long-term survival</variable>
	  <method>linkage to NHS England HES and/or ONS mortality records</method>
	  <timepoints>up to 10 years postoperatively</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c96b3324-1aa9-44d4-a323-05b80cdea09c">
	  <variable>Time to first eating, drinking and walking following surgery,</variable>
	  <method>prospective data collection</method>
	  <timepoints>during the postoperative hospital stay</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="2f9510e9-47dc-4dff-8bcf-c2e052eb902d" approvalStatus="submitted" statusDate="2026-09-10T00:00:00.000Z">
	  <committeeName>South West – Central Bristol Research Ethics Committee</committeeName>
	  <contactDetails>
	    <address>2 Redman Place, Stratford</address>
	    <city>London</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>E20 1JQ</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/SW/0113</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN39538766</doi>
      <eudraCTNumber/>
      <irasNumber>372779</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 74267, NIHR: 206782, 209242</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="38b67e32-694a-4bd9-a7b2-b06afc61b535" numberType="iras" canonicalSecondaryNumber="IRAS372779">372779</secondaryNumber>
	<secondaryNumber id="fb01ffc2-a4a8-41e6-8fc5-7ccd0f80308a" numberType="cpms" canonicalSecondaryNumber="CPMS74267">74267</secondaryNumber>
	<secondaryNumber id="a768e11c-3e91-4d40-ade8-22551a760b7b" numberType="nihr" canonicalSecondaryNumber="NIHR206782">206782</secondaryNumber>
	<secondaryNumber id="7656505d-0a7a-4709-a5bc-46aeb1018371" numberType="Sponsor R&amp;D ID">209242</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Supportive care</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-10-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="61205437-6d88-4637-8ae5-aab75654911c">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>4th Floor
170 Tottenham Court Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W1T 7HA</zip>
	</trialCentre>
	<trialCentre id="efb0135f-989e-4976-b2a1-90b714142571">
	  <name>Blackpool Victoria Hospital</name>
	  <address>Whinney Heys Road</address>
	  <city>Blackpool</city>
	  <state/>
	  <country>England</country>
	  <zip>FY3 8NR</zip>
	  <rtsId>RW5GJ@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="e6b8e9c3-03c8-414f-84eb-3dfaa29adddb">
	  <name>Queen Elizabeth Hospital</name>
	  <address>Mindelsohn Way
Edgbaston</address>
	  <city>Birmingham</city>
	  <state/>
	  <country>England</country>
	  <zip>B15 2GW</zip>
	  <rtsId>RTHH6@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="74f697b5-742b-42d4-976c-db1bdb874800">
	  <name>King's College Hospital</name>
	  <address>Denmark Hill</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
	<trialCentre id="0e8e280e-8cee-4c65-8e1b-d7b0d1808981">
	  <name>St. James' University Hospital</name>
	  <address>Beckett Street</address>
	  <city>Leeds</city>
	  <state/>
	  <country>England</country>
	  <zip>LS9 7TF</zip>
	  <rtsId>RY608@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="10f84ca1-dd4f-466b-815f-44d0ee7ae981">
	  <name>Sunderland Royal Hospital</name>
	  <address>Kayll Road</address>
	  <city>Sunderland</city>
	  <state/>
	  <country>England</country>
	  <zip>SR4 7TP</zip>
	  <rtsId>RXPWE@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="798437d6-cb8e-421b-b547-5f86926217cd">
	  <name>Derriford Hospital</name>
	  <address>Derriford Road
Derriford</address>
	  <city>Plymouth</city>
	  <state/>
	  <country>England</country>
	  <zip>PL6 8DH</zip>
	  <rtsId>RH8D2@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="f26f6b2f-3788-4daa-9ddc-1c1f8bd513f8">
	  <name>Royal Liverpool University Hospital</name>
	  <address>Prescot Street</address>
	  <city>Liverpool</city>
	  <state/>
	  <country>England</country>
	  <zip>L7 8XP</zip>
	  <rtsId>RBN58@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bb045dcd-1a75-4001-a4db-07c3c4fef5b0">
	  <name>Colchester General Hospital</name>
	  <address>Turner Road</address>
	  <city>Colchester</city>
	  <state/>
	  <country>England</country>
	  <zip>CO4 5JL</zip>
	</trialCentre>
	<trialCentre id="3d2ca0c7-7848-48d1-b9a3-6df715f62aaa">
	  <name>Worthing Hospital</name>
	  <address>Lyndhurst Road</address>
	  <city>Worthing</city>
	  <state/>
	  <country>England</country>
	  <zip>BN11 2DH</zip>
	  <rtsId>RDR1D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="bd52c157-611a-4f9b-81a8-f0bf52a97ea2">
	  <name>Freeman Hospital</name>
	  <address>Freeman Road
High Heaton</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE7 7DN</zip>
	  <rtsId>RTD01@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c0b90963-cdfc-40f8-87cd-5ec9953a5657">
	  <name>University College London Hospital</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>K2Z3D@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b5679ae7-abd2-4c91-b64d-3232983c6c62">
	  <name>The James Cook University Hospital</name>
	  <address>Marton Road</address>
	  <city>Middlesbrough</city>
	  <state/>
	  <country>England</country>
	  <zip>TS4 3BW</zip>
	  <rtsId>RTRAT@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="5bf790e8-2408-45cb-96a3-76821dc4af25">
	  <name>Bristol NHS Foundation Trust</name>
	  <address>Trust Headquarters
Marlborough Street</address>
	  <city>Bristol</city>
	  <state/>
	  <country>England</country>
	  <zip>BS1 3NU</zip>
	  <rtsId>RA7@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Age 18 years or older
2. Undergoing elective or expedited major non-cardiac surgery with an expected postoperative hospital length of stay (LOS) of 3 or more days
3. Planned date of surgery between 1 and 6 months from the time of recruitment and randomisation (based on treatment pathway and local waiting times)
4. Able to provide written informed consent
5. Able and willing to complete questionnaires (translated and alternative-format materials available)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>420</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>Age under 18 years on the date of recruitment and randomisation</exclusion>
      <recruitmentStart>2027-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-01-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Socioeconomic inequalities in outcomes after elective or expedited major non-cardiac surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>HIPPOCRATES is a pilot platform (multi-arm, multi-stage) trial comparing three co-designed interventions with standard care. Further interventions may be added by protocol modification.

Arm A (intervention 1): Preoperative optimisation and prehabilitation. From randomisation until surgery (1–6 months), participants complete four validated screening questionnaires covering long-term conditions and health behaviours, cardiorespiratory fitness, nutritional status and psychological health. A named clinical coordinator then triages each domain to Level 1 (generic advice, e.g. leaflets, videos, surgery school), Level 2 (structured non-specialist support, e.g. health coaching, social prescribing, free access to local gyms, an exercise app and online classes, and free protein supplements) or Level 3 (specialist support from a dietitian, psychologist, exercise physiologist or relevant medical specialist).

Arm B (intervention 2): Financial navigation and support. A baseline discussion with a trained clinical staff member, followed by opt-out referral to Citizens Advice for navigation to state benefits, referral to NHS transport support and, if eligible, shopping vouchers up to the value of £200 for patients in financial crisis while benefits are processed. Regular check-ins by text, email or phone before and after surgery give participants the opportunity to opt back into support.

Arm C (intervention 3): Postoperative enhanced surveillance. A wireless wearable monitor (CheckPoint Cardio chest-worn patch and pulse oximeter) worn from leaving the operating theatre, throughout the postoperative hospital stay and for up to 48 hours after discharge, with continuous 24-hour remote monitoring. Alerts are routed through existing hospital escalation pathways (surgical team in hours; critical care outreach team out of hours). Text-message check-ins start during the inpatient stay and continue for up to 30 days after discharge.

Arm D: Standard of care at each NHS provider. Hospitals routinely offering any of the trial interventions are not eligible as trial sites.

Participants are allocated 1:1:1:1 (target 420 participants, 105 per arm). Following the screening visit and allocation of a participant identification number, the PI or delegate will enter the participant's initials, sex, age, date of consent, eligibility and other variables required for minimisation on the SealedEnvelope.com secure online system, which re-confirms eligibility and assigns the treatment arm.</description>
	<interventionType>Mixed</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement>Anonymised individual participant data will be available after the main trial results are published (expected within 12 months of the end of the trial). Requests must be made in writing to UCL CCTU (cctu.hippocrates@ucl.ac.uk), must have a strong scientific or other legitimate rationale, and will be considered by the trial oversight committees and the Chief Investigator.</ipdSharingStatement>
      <dataPolicies>
	<dataPolicy>Available on request</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage>Protocol</publicationStage>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e2ccf5ce-9ed7-4a20-8c6d-d1a1a1099a8f" outputType="protocolfile" artefactType="LocalFile" dateCreated="2026-09-07T00:00:00.000Z" dateUploaded="2026-10-13T00:00:00.000Z" peerReviewed="false" patientFacing="false" createdBy="">
	<localFile fileId="70e28a32-7c01-42d0-bf38-794335ce6ce6" originalFilename="49999_Protocol_v1.0_07Sep2026.pdf" downloadFilename="49999_Protocol_v1.0_07Sep2026.pdf" version="1.0" mimeType="application/pdf" length="1284628" md5sum="6853451cfab6a0ec2129f1058085be37"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>8f3a2dd3-5dca-4abf-a748-3d1fc76f1281</funderId>
      <contactId>5bed5c5f-605f-4d94-9c86-9d58b7a1914d</contactId>
      <sponsorId>02bd339b-209b-4dfb-84fa-e73e1b8289b7</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>Yes</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles>
      <attachedFile downloadUrl="https://www.isrctn.com/editorial/retrieveFile/70e28a32-7c01-42d0-bf38-794335ce6ce6/49999">
	<description>Protocol file</description>
	<name>49999_Protocol_v1.0_07Sep2026.pdf</name>
	<id>70e28a32-7c01-42d0-bf38-794335ce6ce6</id>
	<public>true</public>
	<mimeType>application/pdf</mimeType>
	<length>1284628</length>
	<md5sum>6853451cfab6a0ec2129f1058085be37</md5sum>
      </attachedFile>
    </attachedFiles>
  </trial>
  <contact id="5bed5c5f-605f-4d94-9c86-9d58b7a1914d">
    <title>Prof</title>
    <forename>S. Ramani</forename>
    <surname>Moonesinghe</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Principal investigator</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>University College London Hospitals NHS Foundation Trust
4th Floor
170 Tottenham Court Road</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1T 7HA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 02031086154</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cctu.hippocrates@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="02bd339b-209b-4dfb-84fa-e73e1b8289b7">
    <organisation>University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="8f3a2dd3-5dca-4abf-a748-3d1fc76f1281">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-13T08:05:01.799021676Z" version="11" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN15511645" publicIdentifierDateAssigned="2026-10-13T08:05:01.949394Z">
    <isrctn dateAssigned="2026-10-13T08:05:01.949394Z">15511645</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="true">
      <acknowledgment>true</acknowledgment>
      <title>A study to find out if early microsurgery to repair damaged lymph vessels can reduce arm swelling after lymph node removal surgery for cancer treatment</title>
      <scientificTitle>A feasibility multicentre randomised controlled trial on microsurgical immediate lymphatic reconstruction to reduce risk of lymphoedema</scientificTitle>
      <acronym>CRYPTIC</acronym>
      <studyHypothesis>This study aims to evaluate the feasibility of performing a multicentre randomized controlled trial (RCT) on immediate lymphatic reconstruction in prevention of lymphoedema.</studyHypothesis>
      <plainEnglishSummary>Background and study aims 
Surgery for cancer sometimes requires removal of the lymph nodes in the armpit, known as axillary lymph node clearance (ALNC). While this is often necessary for cancer treatment, it carries a risk of causing lymphoedema, a long-term condition that results in painful and disabling swelling of the arm. Lymphoedema can have a major impact on quality of life and currently there are no proven ways of preventing it.
This study is testing whether it is possible to introduce a new surgical technique, called immediate lymphatic reconstruction (ILR), alongside standard cancer surgery. ILR involves reconnecting small lymphatic vessels to tiny veins in the armpit during the operation. This is done using microsurgery and adds around 60 minutes to the procedure. The aim is to restore lymphatic drainage and reduce the risk of developing lymphoedema in the future.

Who can participate? 
Patients aged 18 years and over with breast cancer or skin cancer of the trunk who need ALNC

What does the study involve? 
Participants will be randomly allocated by computer to one of two groups. One group will receive standard surgery (ALNC alone), while the other group will receive ALNC with ILR. All patients will be followed for up to 2 years. At each follow-up, doctors and nurses will assess the arms for swelling, carry out simple tests such as arm measurements and bioimpedance (a painless electrical measurement), and ask participants to complete questionnaires about wellbeing and quality of life. In some centres, an additional test called indocyanine green (ICG) lymphography may also be used.

What are the possible benefits and risks of participating? 
The main purpose of this feasibility study is to test whether this type of trial is practical and to gather early safety data. If successful, the results will inform the design of a larger trial to properly test whether ILR prevents lymphoedema.

Where is the study run from? 
The Royal Free Hospital (UK)

When is the study starting and how long is it expected to run for? 
October 2026 to September 2029

Who is funding the study? 
The National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
1. Muholan Kanapathy, m.kanapathy@ucl.ac.uk, muholan.kanapathy@nhs.net
2. Naghmeh Naderi, naghmeh.naderi@nhs.net</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="ebf0363e-cfd7-43ff-90cb-8f2450181d19">
	  <variable>Recruitment rate</variable>
	  <method>the number of patients</method>
	  <timepoints>18 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="aba839f6-eb0a-474b-8fc4-fc12cf7b7c0e">
	  <variable>Rate of withdrawal from the study</variable>
	  <method>the number of patients</method>
	  <timepoints>18 months</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="b93243a7-7696-43f5-aa82-98f5c7424365">
	  <variable>Proportion of patients developing lymphoedema</variable>
	  <method>limb circumference measurements and bioimpedence</method>
	  <timepoints>up to 24 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="c463c5a1-ae13-498c-b533-cc7d555703bb">
	  <variable>Health-related quality of life</variable>
	  <method>the Lymphoedema Quality of Life Tool (LYMQoL), the Lymphoedema Life Impact Scale (LLIS) and EQ-5D-5L questionnaires</method>
	  <timepoints>1 month and 6 monthly up to 24 months</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="941f0283-c917-40a5-9637-7cc2e8dda004">
	  <variable>Postoperative complications and adverse events</variable>
	  <method>early and late postoperative complications</method>
	  <timepoints>1 month and 6 monthly up to 24 months</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="4a66026c-1f7c-4ed4-a468-49d840cd14ee" approvalStatus="approved" statusDate="2026-09-07T00:00:00.000Z">
	  <committeeName>West of Scotland REC 4</committeeName>
	  <contactDetails>
	    <address>Research Ethics – Room 29
2nd Floor Administration Building
Gartnavel Royal Hospital
1055 Great Western Road</address>
	    <city>Glasgow</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>G12 0XH</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/WS/0121</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15511645</doi>
      <eudraCTNumber/>
      <irasNumber>375171</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CPMS: 58106</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="7c6a7d86-9afe-4894-a1ca-7b099c8e50a0" numberType="iras" canonicalSecondaryNumber="IRAS375171">375171</secondaryNumber>
	<secondaryNumber id="01ee8a26-d2fb-466f-9121-59bb2ab40d5b" numberType="cpms" canonicalSecondaryNumber="CPMS58106">58106</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	  <purpose>Treatment</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fb9361f8-0433-4fd0-8173-31a53b40fc90">
	  <name>Royal Free London NHS Foundation Trust</name>
	  <address>Royal Free Hospital
Pond Street</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW3 2QG</zip>
	  <rtsId>RAL@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="3c72c89f-8d74-4020-80e6-89485842a404">
	  <name>Charing Cross Hospital</name>
	  <address>Fulham Palace Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>W6 8RF</zip>
	  <rtsId>RYXC1@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="b567f7fc-5d0b-4f27-8cf0-f8a7b597bd33">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>RRV00@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="438dd692-03b2-4d1e-89ef-7972a2a47a9b">
	  <name>The Welsh Centre for Burns and Plastic Surgery</name>
	  <address>Swansea Bay University Health Board
Heol Maes Eglwys</address>
	  <city>Morriston</city>
	  <state/>
	  <country>Wales</country>
	  <zip>SA6 6NL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Adults ≥18 years old
2. Diagnosis of breast cancer or skin cancer of the trunk requiring ALNC (with or without neoadjuvant or adjuvant systemic treatment)
3. Patient understands and is willing to consent, can comply with follow-up regime and able to respond to the questionnaires</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="99.0">99 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Skin cancer of the ipsilateral upper limb requiring surgical excision
2. Fungating axillary lymph node disease requiring soft tissue reconstruction 
3. Inflammatory breast cancer
4. Previous history of upper limb cancer or lymphoedema
5. Prior ipsilateral axillary radiation
6. High risk for general anaesthesia (GA) or not fit for surgery (ASA classification &gt;4)</exclusion>
      <recruitmentStart>2026-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Patients with cancer requiring axillary lymph node clearance (ALNC) as part of their planned surgical treatment</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomisation will be performed on a 1:1 basis (ILR versus non-ILR (control)). Stratification by site will be applied to balance recruitment across the recruiting NHS hospitals. Participants will be deemed enrolled into the study once they have been randomised to either of the study arms. The assessor will be blinded to the allocation.

The control group undergoes axillary lymph node clearance (ALNC) for breast cancer or skin cancer of the trunk.

The intervention group undergoes ALNC and immediate lymphatic reconstruction.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>c89dd27a-4bf7-470b-b6d2-fa27e02229ff</funderId>
      <contactId>352da872-a451-4ec7-be47-9ddcba03614e</contactId>
      <contactId>34b6212c-6e81-4da2-a3a3-77374f0c4434</contactId>
      <sponsorId>40a78dbe-77c7-4255-aa06-75fe1464288d</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="352da872-a451-4ec7-be47-9ddcba03614e">
    <title>Mr</title>
    <forename>Muholan</forename>
    <surname>Kanapathy</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Free Hospital London NHS Foundation Trust</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>NW3 2QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7794 0500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">muholan.kanapathy@nhs.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="34b6212c-6e81-4da2-a3a3-77374f0c4434">
    <title>Ms</title>
    <forename>Naghmeh</forename>
    <surname>Naderi</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Free Hospital London NHS Foundation Trust</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>NW32QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7794 0500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">naghmeh.naderi@nhs.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="40a78dbe-77c7-4255-aa06-75fe1464288d">
    <organisation>The Royal Free Hospital</organisation>
    <sponsorType/>
    <rorId>https://ror.org/01ge67z96</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="c89dd27a-4bf7-470b-b6d2-fa27e02229ff">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-28T07:46:40.19754802Z" version="24" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN97585476" publicIdentifierDateAssigned="2026-09-28T07:46:40.330766Z">
    <isrctn dateAssigned="2026-09-28T07:46:40.330766Z">97585476</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of novel thrombolytic TGD001 in patients with acute ischemic stroke</title>
      <scientificTitle>A Phase Ib/IIa open-label dose-finding followed by randomized, double-blind, placebo-controlled expansion study to evaluate the safety, tolerability, and preliminary efficacy of TGD001 in patients with acute ischemic stroke</scientificTitle>
      <acronym>TG1-CL-201</acronym>
      <studyHypothesis>Primary objective:
To assess the safety and tolerability of single intravenous (IV) doses of TGD001 in participants with an acute ischemic stroke (AIS) diagnosis, supported by neuroimaging, who either receive endovascular thrombectomy (EVT) or do not receive EVT or standard of care (SOC) intravenous thrombolysis (IVT).

Secondary objectives:
1. To assess the rates of asymptomatic intracranial hemorrhage (aICH)
2. To determine the pharmacokinetic (PK) profile of single IV doses of TGD001 in participants with AIS 
3. To assess recanalization post-intervention
4. To assess reperfusion post-intervention
5. To assess neurological outcome at 90 days post-intervention
6. To determine the functional status at 90 days post-intervention</studyHypothesis>
      <plainEnglishSummary>Background and study aims
An acute ischaemic stroke happens when a blood clot blocks blood flow to part of the brain. This can damage brain tissue and may cause long-term disability. Current treatments include medicines that dissolve blood clots and a procedure to remove the clot, called thrombectomy. However, these treatments do not always work well enough, so better treatments are needed.
This study is testing a new clot-dissolving medicine called TGD001. TGD001 targets a part of blood clots called von Willebrand factor, which is different from the main target of currently used clot-dissolving medicines. The main aim of the study is to find out whether TGD001 is safe and well tolerated in people who have had an acute ischaemic stroke. The study will also look at how TGD001 affects blood flow in the brain and recovery after stroke.

Who can participate?
Adults aged 18 years or older who have had an acute ischaemic stroke confirmed by a brain scan may be able to take part. This includes some people who have had a thrombectomy and some people who are not suitable for standard clot treatments. Men and women can take part, but women who are pregnant or breastfeeding cannot participate. 

What does the study involve?
About 130 people will take part at specialist stroke hospitals.
The study has two parts. In the first part, small groups of participants receive a single dose of TGD001 into a vein. Different doses are studied to help identify a suitable dose for further testing. In the second part, participants are randomly assigned to receive either TGD001 or a placebo treatment. Neither the participant nor most of the study team will know which treatment was given.
Participants will continue to receive the standard stroke care that is appropriate for them. During the study, doctors will monitor participants for side effects. Participants will also have blood tests, brain scans and assessments of their stroke symptoms and ability to carry out everyday activities. Each participant will be followed for about 90 days. 

What are the possible benefits and risks of participating?
Participants may or may not benefit directly from taking part. TGD001 may help dissolve blood clots and improve blood flow to the brain, but it is not yet known whether it will improve recovery from stroke. Participants will also be closely monitored during the study. The information collected may help researchers better understand TGD001 and may contribute to better treatments for people with stroke in the future.
The main potential risk of TGD001 is bleeding, which may occur in the brain or elsewhere in the body. There is also a possibility of an allergic or treatment-related reaction. Blood tests, brain scans and other study procedures may also cause discomfort or carry small risks. Participants will be monitored and treated if any problems occur.

Where is the study run from?
The study is managed by TargED Biopharmaceuticals B.V. in Utrecht, the Netherlands. 

When is the study starting and how long is it expected to run for?
March 2026 to December 2027

Who is funding the study?
TargED Biopharmaceuticals B.V. (Netherlands)

Who is the main contact?
Sonja Visscher, clinops@targedbio.com</plainEnglishSummary>
      <primaryOutcomes/>
      <primaryOutcome>1. Symptomatic intracranial haemorrhage (sICH) is assessed according to the Heidelberg Bleeding Classification during the post-intervention follow-up (90 days)
2. Treatment-emergent adverse events (TEAEs) are assessed by standard adverse-event monitoring throughout the study follow-up period up to Day 90</primaryOutcome>
      <secondaryOutcomes/>
      <secondaryOutcome>1. Asymptomatic intracranial haemorrhage (aICH) is assessed by brain imaging during post-intervention follow-up (90 days)
2. Pharmacokinetics of TGD001 are assessed from plasma TGD001 concentrations and derived pharmacokinetic parameters, including Cmax, Tmax, AUC and t½, using serial blood samples collected at baseline and up to six timepoints 72 hours after treatment
3. Recanalization is assessed using computed tomography angiography (CTA) or magnetic resonance angiography (MRA) during post-intervention follow-up (90 days)
4. Reperfusion/perfusion deficit is assessed using computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP) during post-intervention follow-up (90 days)
5. Neurological outcome is assessed using the National Institutes of Health Stroke Scale (NIHSS) during post-intervention follow-up and at Day 90
6. Functional outcome is assessed using the modified Rankin Scale (mRS) during follow-up and at Day 90</secondaryOutcome>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="2ec89659-67b3-403a-8486-ed5349faaa57" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97585476</doi>
      <eudraCTNumber/>
      <irasNumber>1013913</irasNumber>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>TG1-CL-201</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="bf0914db-da4a-48e1-9b67-f2b47e00bb6d" numberType="iras" canonicalSecondaryNumber="IRAS1013913">1013913</secondaryNumber>
	<secondaryNumber id="aaf7e0f0-870e-4f9b-8b25-9f8c5eb2b9a0" numberType="Sponsor's protocol code number">TG1-CL-201</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Blinded (masking used)</masking>
	<control>Placebo</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	  <purpose>Safety</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Efficacy</trialType>
	<trialType>Safety</trialType>
	<trialType>Treatment</trialType>
	<trialType>Other</trialType>
      </trialTypes>
      <overallEndDate>2027-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
	<country>Belgium</country>
	<country>France</country>
	<country>Germany</country>
	<country>Netherlands</country>
	<country>Poland</country>
	<country>Serbia</country>
	<country>Spain</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="09ed29fd-a2ca-4345-ae2e-a9506d34b08c">
	  <name>Royal Stoke University Hospital</name>
	  <address>Newcastle Road</address>
	  <city>Stoke-on-trent</city>
	  <state/>
	  <country>England</country>
	  <zip>ST4 6QG</zip>
	  <rtsId>RJE01@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="c9e02747-642b-4d83-869d-4cb60a9c1938">
	  <name>Kings College Hospital</name>
	  <address>Denmark Hill</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>SE5 9RS</zip>
	</trialCentre>
	<trialCentre id="9eba12af-6852-47d2-ad1b-fbf063c1934e">
	  <name>Royal Victoria Infirmary</name>
	  <address>Queen Victoria Road</address>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>England</country>
	  <zip>NE1 4LP</zip>
	  <rtsId>RTFEC@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="987cf506-7a72-47af-9fa1-81e1bed93eec">
	  <name>University College London Hospitals NHS Foundation Trust</name>
	  <address>250 Euston Road</address>
	  <city>London</city>
	  <state/>
	  <country>England</country>
	  <zip>NW1 2PG</zip>
	  <rtsId>RRV00@2.16.840.1.113883.2.1.3.2.4.18.48</rtsId>
	</trialCentre>
	<trialCentre id="7d6686ec-fd2d-4d37-8805-17b28814f749">
	  <name>University Hospital Hamburg-Eppendorf</name>
	  <address>Martinistrasse 52</address>
	  <city>Hamburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>20246</zip>
	</trialCentre>
	<trialCentre id="86d3c11f-61b3-4290-9a7d-e409ffca6909">
	  <name>Klinikum Altenburg Land</name>
	  <address>Am Waldessaum 10</address>
	  <city>Altenburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>4600</zip>
	</trialCentre>
	<trialCentre id="5f93c7bf-39c9-48f9-b78a-9d78df588ee9">
	  <name>Universitätsklinikum Heidelberg</name>
	  <address>Im Neuenheimer Feld 400</address>
	  <city>Heidelberg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>69120</zip>
	</trialCentre>
	<trialCentre id="8a84e275-8e75-4a15-b88a-da7ed61feda7">
	  <name>Klinikum Ernst von Bergmann</name>
	  <address>Charlottenstraße 72</address>
	  <city>Potsdam</city>
	  <state/>
	  <country>Germany</country>
	  <zip>14467</zip>
	</trialCentre>
	<trialCentre id="2788c526-3c06-49a9-ae6e-d17c3c833e20">
	  <name>Uniklinikum Dresden</name>
	  <address>Fetscherstraße 74</address>
	  <city>Dresden</city>
	  <state/>
	  <country>Germany</country>
	  <zip>1307</zip>
	</trialCentre>
	<trialCentre id="2143ff01-0c39-4f93-a670-3c5d189e3f83">
	  <name>Universitätsklinikum Bonn</name>
	  <address>Venusberg Campus 1</address>
	  <city>Bonn</city>
	  <state/>
	  <country>Germany</country>
	  <zip>53127</zip>
	</trialCentre>
	<trialCentre id="c0358efa-66e4-4158-8d98-9fc5233bfd34">
	  <name>Universitätsklinikum Tübingen</name>
	  <address>Hoppe-Seyler-Str. 3</address>
	  <city>Tübingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>72076</zip>
	</trialCentre>
	<trialCentre id="89a928ea-90b5-4821-b4fc-4b4ecb5bb58d">
	  <name>Universitätsmedizin Charité</name>
	  <address>Hindenburgdamm 30a</address>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12203</zip>
	</trialCentre>
	<trialCentre id="23d9eea4-2dd9-49cd-bd80-7205aba4b233">
	  <name>Hospital Universitario Virgen Macarena</name>
	  <address>Avenida Dr. Fedriani 3</address>
	  <city>Sevilla</city>
	  <state/>
	  <country>Spain</country>
	  <zip>41008</zip>
	</trialCentre>
	<trialCentre id="b7453c10-f4a4-4504-8b93-cee4d58d542a">
	  <name>Hospital Germans Trias i Pujol</name>
	  <address>Carretera de Canyet 8916, Badalona</address>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>Badalona</zip>
	</trialCentre>
	<trialCentre id="4db506f7-4c3a-4598-89cf-02da9d5f9b9c">
	  <name>Hospital Virgen de la Arrixaca</name>
	  <address>Caretta Madrid-Cartagena, El Palmar</address>
	  <city>Murcia</city>
	  <state/>
	  <country>Spain</country>
	  <zip>30120</zip>
	</trialCentre>
	<trialCentre id="5937fb23-214b-4746-b5d7-c8102563deaa">
	  <name>Hospital Álvaro Cunqueiro</name>
	  <address>Estrada de Clara Campoamor 341, Vigo</address>
	  <city>Pontevedra</city>
	  <state/>
	  <country>Spain</country>
	  <zip>36312</zip>
	</trialCentre>
	<trialCentre id="a84ccb98-1903-4a0c-817f-68c7914fb912">
	  <name>Hospital Universitario Virgen del Rocío</name>
	  <address>Avenida Manuel Siurot</address>
	  <city>Sevilla</city>
	  <state/>
	  <country>Spain</country>
	  <zip>41013</zip>
	</trialCentre>
	<trialCentre id="7ecec3ef-c238-4723-8ac9-19e52f534538">
	  <name>Hospital Universitari Vall d'Hebron</name>
	  <address>Pg. de la Vall d'Hebron, 119</address>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>8035</zip>
	</trialCentre>
	<trialCentre id="1268bf0a-5bc4-4a8c-a4f9-91fe88a370c4">
	  <name>Hospital Clínico Universitario de Valladolid</name>
	  <address>Avenida de Ramón y Cajal 3</address>
	  <city>Valladolid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>47003</zip>
	</trialCentre>
	<trialCentre id="c53273f1-2d3e-4d7c-b977-2330be576bcf">
	  <name>Hospital Universitari de Girona</name>
	  <address>Avinguda de França</address>
	  <city>Girona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>17007</zip>
	</trialCentre>
	<trialCentre id="28de0555-baeb-4d41-abe7-4a5ef87f3811">
	  <name>University Hospital in Krakow</name>
	  <address>Macieja Jakubowskiego 2</address>
	  <city>Krakow</city>
	  <state/>
	  <country>Poland</country>
	  <zip>30-688</zip>
	</trialCentre>
	<trialCentre id="39eb7573-14dc-42dd-ba86-1a4db7df93f5">
	  <name>Górnoslaskie Centrum Medyczne im. Leszka</name>
	  <address>Gieca Slaskiego Uniwersytetu Medycznego w
Katowicach ul. Ziołowa 45-47</address>
	  <city>Katowice</city>
	  <state/>
	  <country>Poland</country>
	  <zip>40-635</zip>
	</trialCentre>
	<trialCentre id="d2bfd467-aef2-4794-803d-1d004cab9534">
	  <name>Military Medical Academy</name>
	  <address>Crnotravska 17</address>
	  <city>Belgrade</city>
	  <state/>
	  <country>Serbia</country>
	  <zip>11000</zip>
	</trialCentre>
	<trialCentre id="d18fd2b5-d5ee-4ec6-b624-445c91386b61">
	  <name>University Clinical Center Nis</name>
	  <address>dr Zoran Djindjic Boulevard 48</address>
	  <city>Nis</city>
	  <state/>
	  <country>Serbia</country>
	  <zip>18000</zip>
	</trialCentre>
	<trialCentre id="a929bc14-ee96-45b9-91b5-66cea8e1060b">
	  <name>University Clinical Center Kragujevac</name>
	  <address>Zmaj Jovina 30</address>
	  <city>Kragujevac</city>
	  <state/>
	  <country>Serbia</country>
	  <zip>34000</zip>
	</trialCentre>
	<trialCentre id="1a06c104-b947-4945-8984-f8e0d02293fb">
	  <name>University Clinical Centre of Vojvodina</name>
	  <address>Hajduk Veljkova 1</address>
	  <city>Novi Sad</city>
	  <state/>
	  <country>Serbia</country>
	  <zip>21137</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1. Age ≥18 years
2. Informed consent obtained from the participant or a participant representative in accordance with local legal and institutional review board (IRB) and independent ethics committee (IEC) requirements
3. Functionally independent (Modified Rankin Scale [mRS] 0-2) prior to stroke onset
4. Diagnosis of AIS supported by neuroimaging:
4.1. A visible occlusion on computed tomography angiography (CTA) or magnetic resonance angiography (MRA) imaging; and/or
4.2. An ischemic lesion ( Alberta stroke program early CT score [ASPECTS] 6 - 10) on non-contrast computed tomography (NCCT) or magnetic resonance imaging (MRI), with target mismatch on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP) imaging, if performed
5. National Institutes of Health Stroke Scale (NIHSS) ≥5 and that remains ≥5 immediately before enrollment
6. Participants who:
6.1. Meet the local endovascular thrombectomy (EVT) eligibility requirements and undergo EVT (Groups 1 and 2), or 
6.2. Do not receive EVT or SOC IVT (Group 3)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="100.0">100 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1. Unable to undergo both MRI and CT imaging
2. Intracranial hemorrhage on pre-intervention imaging
3. Demarcated infarct or early ischemic changes resulting in ASPECTS ≤5 on pre-intervention imaging
4. Active internal bleeding
5. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
6. Use of an anticoagulant, including but not limited to direct oral anticoagulants (DOACs) or warfarin, within the last 48 hours or recent oral anticoagulant therapy with international normalized ratio (INR) ≥1.7. If the DOAC level is measured and found to be below the therapeutic threshold (Factor Xa inhibitor levels of less than 50 ng/ml or anti-Xa levels of less than 0.5 IU/ml), the participant can be enrolled regardless of the recency of the last dose.
7. Use of any medication and/or recent procedure that is known to significantly increase the bleeding risk (at the discretion of the investigator)
8. More than four recanalization attempts of target lesion with stent retriever or aspiration device during EVT prior to the use of the trial intervention
9. Coma, and/or NIHSS &gt;25 
10. Seizure(s) at stroke onset if this precludes obtaining an accurate baseline NIHSS
11. Severe, uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;110 mmHg). NOTE: If the blood pressure can be successfully reduced and maintained at an acceptable level using European Stroke Organization (ESO) guidelines-recommended medication (including i.v. antihypertensive drips), the participant can be enrolled.
12. Platelet count &lt;100.000/µl
13. Blood glucose &lt;50 mg/dl (2.8 mmol/l) or &gt;400 mg/dL (22.20 mmol/l)
14. Impaired renal function as indicated by estimated glomerular filtration rate (GFR) below 30 ml/min/1.73 m² or requiring hemodialysis/peritoneal dialysis
15. Severe liver fibrosis or portal hypertension
16. Female who is pregnant, lactating, or has a positive pregnancy test at the time of admission
17. Evidence of active systemic infection that could have led to presumed septic embolus, suspicion of bacterial endocarditis
18. Surgery or trauma affecting intracranial or intraspinal areas within the last 2 months
19. Pre-existing severe medical, neurological, or psychiatric disease that would significantly confound the neurological or functional evaluations (investigator judgment) 
20. History of cerebrovascular incident in the last 3 months
21. Intracranial neoplasm, arteriovenous malformation, or aneurysm
22. Other serious, advanced, or terminal illness in the last 3 months (investigator judgment) or life expectancy is less than 6 months
23. Known hypersensitivity to any of the trial treatments or their excipients or to drugs of similar chemical classes
24. Participant participating in a trial involving an investigational drug or device that would impact this trial within the last 30 days</exclusion>
      <recruitmentStart>2026-03-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2027-12-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The trial consists of two parts and includes prespecified groups of participants with acute ischemic stroke.

Phase 1b is an open-label, single-dose escalation and expansion phase. Participants receive one intravenous administration of TGD001. Dose-escalation and de-escalation decisions are overseen by the Data Safety Monitoring Committee (DMC), which will select the dose or doses for further evaluation. Three dose levels are planned for each patient group. Additional dose levels may be established by the DMC. 

Phase 2a is a randomized, double-blind, placebo-controlled expansion phase. Participants receive one intravenous administration of either TGD001 or placebo. Randomisation occurs before treatment according to a prespecified randomisation schedule.

All participants are followed for approximately 90 days. Follow-up includes safety assessments, laboratory and pharmacokinetic/pharmacodynamic sampling, brain imaging, and neurological and functional outcome assessments.</description>
	<interventionType>Drug</interventionType>
	<phase>Phase II</phase>
	<drugNames>TGD001</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>db29f236-23c5-4f8b-aa3d-2a0291fbe736</funderId>
      <contactId>10c7b714-113a-43d4-b301-c18cc55ef714</contactId>
      <contactId>4a40f9a8-b842-4bf7-a462-f0767e8767b7</contactId>
      <contactId>39daec96-d8ea-43b7-a53b-fbc6e870692d</contactId>
      <sponsorId>29907399-4adf-4d09-b148-e286c697fc62</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="10c7b714-113a-43d4-b301-c18cc55ef714">
    <title>Dr</title>
    <forename>Josefin-Beate</forename>
    <surname>Holz</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Princetonlaan 6</address>
      <city>Utrecht</city>
      <state/>
      <country>Netherlands</country>
      <zip>3584 CB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2028079 ext 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">regulatory@Targedbio.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="4a40f9a8-b842-4bf7-a462-f0767e8767b7">
    <title>Dr</title>
    <forename>Sonja</forename>
    <surname>Visscher</surname>
    <orcid/>
    <contactTypes>
      <contactType>Scientific</contactType>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>Princetonlaan 6</address>
      <city>Utrecht</city>
      <state/>
      <country>Netherlands</country>
      <zip>3584 CB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2028079 ext 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinops@targedbio.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="39daec96-d8ea-43b7-a53b-fbc6e870692d">
    <title>Dr</title>
    <forename>Christine</forename>
    <surname>Roffe</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>Guy Hilton Research Centre
1 Thornburrow Drive</address>
      <city>Stoke-on-Trent</city>
      <state/>
      <country>United Kingdom</country>
      <zip>ST4 7QB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 679484</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Christine.Roffe@uhnm.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="29907399-4adf-4d09-b148-e286c697fc62">
    <organisation>TargED Biopharmaceuticals B.V.</organisation>
    <sponsorType/>
    <commercialStatus>Commercial</commercialStatus>
  </sponsor>
  <funder id="db29f236-23c5-4f8b-aa3d-2a0291fbe736">
    <name>TargED Biopharmaceuticals B.V.</name>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-09-22T10:07:20.865919574Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN15612522" publicIdentifierDateAssigned="2026-09-22T10:07:21.082819Z">
    <isrctn dateAssigned="2026-09-22T10:07:21.082819Z">15612522</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Trial to establish whether dapagliflozin and spironolactone in patients with severe aortic stenosis undergoing aortic valve replacement result in better left ventricular mass regression, myocardial health and patient-reported outcomes than standard-of-care therapy alone</title>
      <scientificTitle>Regression in left ventricular hypertrophy and fibrosis in aortic stenosis – a randomised controlled trial (RELIEF-AS)</scientificTitle>
      <acronym>RELIEF-AS</acronym>
      <studyHypothesis>To evaluate the effects of dapagliflozin, spironolactone, and their combination on myocardial hypertrophy, as measured by the indexed left ventricular mass post-AVR and assessed at 12 months post-randomisation, accounting for baseline, in patients with severe aortic stenosis treated by surgical AVR or TAVI.

•	Assess the impact of these interventions at 12 months post-randomisation on: 
o	myocardial function (global longitudinal strain),
o	exercise capacity (6-minute walk test), 
o	quality-of-life outcome (KCCQ, EQ-5D-5L). 
•	Explore the safety and tolerability of these treatments in the post-AVR population.
•	Assess impact on outcome measures (All-cause mortality and cardiovascular mortality; heart failure hospitalisation; stroke and myocardial infarction; permanent pacemaker implantation).
•	Assess the mechanism of these interventions post-AVR, assessed at 12 months post-randomisation.
•	To assess myocardial fibrosis regression post-AVR, assessed at 12 months post-randomisation, as measured by cardiac MRI-derived indexed extracellular volume (iECV). In addition to iECV, other imaging measures of fibrosis, such as native T1 and ECV%, will be explored to understand the broader effects of dapagliflozin and spironolactone on the myocardium.</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Aortic stenosis is a condition in which the heart's main valve becomes narrowed, making it harder for blood to flow out of the heart. People with severe aortic stenosis often need either surgery or a minimally invasive procedure to replace the damaged valve. Although valve replacement can improve symptoms and help people live longer, some patients continue to experience damage to the heart muscle, which may increase their risk of heart failure and reduce their quality of life.

Two medicines, dapagliflozin and spironolactone, are already used to treat heart failure and have been shown to improve heart health. Researchers want to find out whether these medicines can also help the heart recover after aortic valve replacement in people with severe aortic stenosis who do not have diagnosed heart failure.

This study aims to determine whether dapagliflozin, spironolactone, or a combination of both medicines can improve recovery of the heart muscle after aortic valve replacement compared with standard care alone. Researchers will assess changes in heart structure, heart function, exercise capacity, quality of life and heart muscle scarring.

Who can participate?
Adult patients aged 18 years and over with severe aortic stenosis who are scheduled to undergo surgical or transcatheter aortic valve replacement and who meet the study eligibility criteria.

What does the study involve?
Participants will be randomly assigned to one of four groups to receive either dapagliflozin for 12 months, spironolactone for 12 months, a combination of dapagliflozin and spironolactone for 12 months or standard care without additional study medication.

Participants will undergo assessments before starting treatment and again after 12 months. These assessments include MRI scans of the heart, echocardiograms, blood tests, questionnaires about quality of life, and a six-minute walking test. Additional safety monitoring will be carried out during the study to check kidney function and monitor for possible side effects of the medicines.

What are the possible benefits and risks of participating?
 Participants may not experience direct health benefits from taking part. However, the medicines being studied may help the heart recover more effectively after valve replacement. The findings could lead to improved treatment for future patients with severe aortic stenosis.

Possible risks include side effects related to the study medicines, such as dizziness, dehydration, genital infections, breast tenderness, nausea or raised potassium levels. Some participants may also experience temporary discomfort during blood tests or MRI scans. To reduce these risks, participants will receive regular monitoring and safety checks throughout the study.

Where is the study run from?
The study is sponsored by the Comprehensive Clinical Trials Unit at University College London and is being conducted in the UK.

When is the study starting and how long is it expected to run for?
The first participants are expected to be enrolled in December 2026. Recruitment is planned to continue until August 2028, and the study is expected to finish in February 2030.

Who is funding the study?
The National Institute for Health and Care Research (NIHR) UK.

Who is the main contact?
cctu.relief-as@ucl.ac.uk</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="3a82dfbe-05d8-4f38-867c-4ed0e5c93998">
	  <variable>Left Ventricular Mass Index (LVMi)</variable>
	  <method>cardiac MRI in g/m2</method>
	  <timepoints>baseline and 12 months post-randomisation</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="4e93ba3e-3bfd-41bf-99f2-ed6c20b17f71">
	  <variable>Myocardial function</variable>
	  <method>ejection fraction, global longitudinal strain, and quantitative myocardial stress perfusion</method>
	  <timepoints>baseline and month 12 post-randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="dc65e019-d777-4d06-b552-0f721df2543d">
	  <variable>Myocardial fibrosis</variable>
	  <method>cardiac magnetic resonance (CMR) imaging combined with blood testing to assess indexed extracellular volume (iECV), native T1 and extracellular volume (ECV)</method>
	  <timepoints>baseline and month 12 post-randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="59bf61c6-809c-4983-b45c-e7911ee12e57">
	  <variable>Safety and tolerability of interventions from randomisation to 12 months post-randomisation</variable>
	  <method>the incidence of adverse events and participant clinical events reported on electronic Case Report Forms (CRF), collected</method>
	  <timepoints>the end of the study</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="095aa8a3-357b-43d2-ac63-290324693af4">
	  <variable>Efficacy assessed via quality of life,</variable>
	  <method>the Kansas City Cardiomyopathy Questionnaire and the EQ-5D-5L</method>
	  <timepoints>baseline, month 3, month 6, month 9 and month 12 post-randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="8570f03a-39f6-48fb-a5ee-810aabde9b32">
	  <variable>Efficacy assessed via exercise capacity</variable>
	  <method>the 6-minute walk test</method>
	  <timepoints>baseline and month 12 post-randomisation</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="555a6681-788d-4aa2-b135-83abd10b4ee9">
	  <variable>Exploratory outcome: Pharmacodynamic effects of the interventions on myocardial stress and fibrosis</variable>
	  <method>standard laboratory methods to quantify biomarkers (NT-proBNP, collagen and hs-Troponin)</method>
	  <timepoints>baseline and month 12 post-randomisation</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="92634878-9f6c-4e4c-94e6-fe7cfab3e7be" approvalStatus="approved" statusDate="2026-09-21T00:00:00.000Z">
	  <committeeName>North of Scotland Research Ethics Service</committeeName>
	  <contactDetails>
	    <address>Summerfield House</address>
	    <city>Aberdeen</city>
	    <state/>
	    <country>United Kingdom</country>
	    <zip>AB15 6RE</zip>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference>26/LO/0607</committeeReference>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15612522</doi>
      <eudraCTNumber/>
      <irasNumber>1010996</irasNumber>
      <clinicalTrialsGovNumber>NCT07539259</clinicalTrialsGovNumber>
      <protocolSerialNumber/>
      <secondaryNumbers>
	<secondaryNumber id="17e1c315-959e-4761-8e50-0dec0e4edf37" numberType="nct" canonicalSecondaryNumber="NCT07539259">NCT07539259</secondaryNumber>
	<secondaryNumber id="10b79837-7c28-4bc5-8611-80ee01ec60e3" numberType="iras" canonicalSecondaryNumber="IRAS1010996">1010996</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Parallel</assignment>
	<purposes>
	  <purpose>Treatment</purpose>
	  <purpose>Safety</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes>
	<trialType>Efficacy</trialType>
	<trialType>Safety</trialType>
	<trialType>Treatment</trialType>
	<trialType>Other</trialType>
      </trialTypes>
      <overallEndDate>2030-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="262df4d3-c4d8-41c7-a9ec-eb17c3203cf4">
	  <name>-</name>
	  <address>-</address>
	  <city>-</city>
	  <state/>
	  <country>England</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>false</healthyVolunteersAllowed>
      <inclusion>1.	Participants ≥ 18 years
2.	Left Ventricular Ejection Fraction (LVEF) ≥40%
3.	Diagnosed with severe aortic stenosis* by a cardiologist or cardiac surgeon. Severity of AS follows international guideline criteria, namely at least one of: 
3.1.	Effective orifice area [EOA] &lt;1.0 cm2
3.2.	Indexed EOA of ≤0.6 cm2/m2
3.3.	Peak velocity ≥4.0 m/s or mean gradient &gt;40 mmHg. * including severe low-flow, low-gradient AS
4.	Referred for surgical or transcatheter AVR
5.	Able to provide informed consent and comply with study procedures</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="18.0">18 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="120.0">120 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>520</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.	Current use, intolerance or hypersensitivity to MRAs or SGLT2 inhibitors
2.	Hyperkalaemia (K&gt;5.0 mmol/L) 
3.	Significant renal impairment (eGFR &lt; 45 mL/min/1.73m²)
4.	Severe hepatic insufficiency*
5.	Concomitant severe other valve lesion (severe MR, MS or AR)
6.	Contraindications to MRAs:
6.1.	Addison's disease
6.2.	Acute porphyrias
6.3.	Receiving potassium-sparing diuretics, potassium supplements or strong inhibitors of CYP 3A4 (for example. itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone)
7.	Contraindications to SGLT2-inhibitors:
7.1.	Active urinary tract infections
7.2.	At risk or with a history of diabetic ketoacidosis 
8.	Type 1 or Type 2 Diabetes on insulin
9.	Concomitant diagnosis affecting trial participation or life expectancy of less than two years
10.	Contraindications to MRI (e.g. non-conditional cardiac pacemaker, severe claustrophobia, inability to lie flat: participants who do not meet local safety rules for MRI). Conditional pacemakers/ICDs, if implanted after the baseline scan, are not an exclusion.
11.	Ongoing participation in another CTIMP interventional clinical trial (i.e. drug trial), will not be permitted. Participation in any other trial will need to be discussed with the trial investigators.
12.	Significant comorbidities that would contraindicate participation, including uncontrolled hypertension, or recent myocardial infarction (within 3 months prior to screening)
13.	Pregnancy or breastfeeding, or females of childbearing potential not using an effective method of contraception
14.	Any other medical or psychiatric condition that would interfere with participation or compliance with study procedures as determined by the Principal Investigator (PI)

*As evidenced by features of decompensated cirrhosis e.g. hepatic encephalopathy, ascites, jaundice or markedly deranged liver blood tests e.g. elevated bilirubin, serum albumin &lt;30 or deranged clotting</exclusion>
      <recruitmentStart>2026-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2028-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Aortic stenosis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomisation 1:1:1:1 via Sealed Envelope to either of:
Arm 1 
Dapagliflozin Oral tablet, 10 mg once daily, initiated post- randomisation and continued for 12 months 

Arm 2 
Spironolactone Oral tablet, 25 mg once daily, initiated post- randomisation and continued for 12 months *

Arm 3  
Combination therapy: Dapagliflozin and Spironolactone.
Oral dapagliflozin tablet 10 mg once daily, spironolactone 25 mg once daily, initiated post- randomisation and continued for 12 months *

Arm 4  
Control: Standard post-AVR clinical care.
Routine NHS follow-up after AVR with no additional study drug.

* Some patients on Spironolactone may experience nausea or gynaecomastia (~1/10 men) and will be switched to eplerenone 25 mg once daily in line with standard clinical practice.</description>
	<interventionType>Drug</interventionType>
	<phase>Phase II</phase>
	<drugNames>Dapagliflozin, spironolactone, eplerenone</drugNames>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Data sharing statement to be made available at a later date</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>b321ec5c-a8fd-4ce6-9550-12936d93d0a5</funderId>
      <contactId>fe42c47b-4873-4a2b-8eb0-b7ba0ee1d055</contactId>
      <contactId>3949421b-7f6e-4825-94f4-1b57fc585600</contactId>
      <sponsorId>39fbe8a6-fa5d-4a9c-85ae-b8535200a92d</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="fe42c47b-4873-4a2b-8eb0-b7ba0ee1d055">
    <title>None</title>
    <forename>CCTU trial team</forename>
    <surname>-</surname>
    <orcid/>
    <contactTypes>
      <contactType>Public</contactType>
    </contactTypes>
    <contactDetails>
      <address>90 High Holborn</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1V 6LJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7670 ext 4781</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cctu.relief-as@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="3949421b-7f6e-4825-94f4-1b57fc585600">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Treibel</surname>
    <orcid/>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St Bartholomew’s Hospital</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>EC1A 7BE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">thomas.treibel.12@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="39fbe8a6-fa5d-4a9c-85ae-b8535200a92d">
    <organisation>Comprehensive Clinical Trials Unit at University College London</organisation>
    <sponsorType/>
    <rorId>https://ror.org/02jx3x895</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="b321ec5c-a8fd-4ce6-9550-12936d93d0a5">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2026-10-14T13:47:56.634857168Z" version="13" isPublished="true" publicIdentifierType="isrctn" publicIdentifierCanonical="ISRCTN18103637" publicIdentifierDateAssigned="2026-09-21T12:45:51.493901Z">
    <isrctn dateAssigned="2026-09-21T12:45:51.493901Z">18103637</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A mental health trial of the ‘Learning Together for Mental Health’ intervention in English secondary schools, nested within a trial exploring its impact on education</title>
      <scientificTitle>Examining the effectiveness, cost-effectiveness and mechanisms of 'Learning Together for Mental Health' on mental health outcomes: a nested, cluster randomised controlled trial in English secondary schools</scientificTitle>
      <acronym/>
      <studyHypothesis>The study aim is to examine the effectiveness, cost-effectiveness and mechanisms of the 'Learning Together for Mental Health' (LTMH) whole-school intervention in terms of its mental health outcomes in a cluster randomised controlled trial and answer the following research questions:
1.	What are the effects of LTMH in intention-to-treat (ITT) analyses on student-reported psychological difficulties (primary outcome), and various pre-hypothesised secondary mental health outcomes?
2.	Are effects moderated by student baseline mental health, sex, gender, ethnicity, deprivation or sexual orientation, or school characteristics?
3.	Are effects greater in analyses accounting for intervention fidelity?
4.	What are the effects for pre-specified subgroups (students eligible for free school meals, students with higher reported psychological difficulties at baseline, student with non-white ethnicity, sexual minorities, girls and boys)?
5.	Is the intervention cost-effective?
6.	What do qualitative and quantitative data suggest about mechanisms by which the intervention generates mental health impacts?
7.	What do the trial findings suggest about the intervention theory of change and transferability?</studyHypothesis>
      <plainEnglishSummary>Background and study aims
Adolescence is an important period when many mental health problems emerge. These problems tend to worsen during secondary school. Poor mental health in adolescence can lead to problems such as self-harm, suicide, drug and alcohol dependence, poor school attendance and lower educational achievement. Mental health problems in adolescence can also have lasting effects for physical, social and mental wellbeing in adulthood.
Programs in schools that target the context and culture, rather than individual students, are a promising way to improve student mental health. Some years ago, we tested such a program (called Learning Together) to reduce bullying in English secondary schools. We found that this program not only reduced bullying but also improved student mental health and GCSE results. We worked with the latest research, teachers and students, to adapt this program so it directly focused on mental health. We called it ‘Learning Together for Mental Health’ (LTMH). We also tested this new LTMH program in four secondary schools. We found it was well-liked and considered useful by teachers and students.
An educational charity, the Education Endowment Foundation (EEF), is running large study with 140 schools to see if LTMH can improve educational achievement. We want to embed a mental health study, looking at effect of LTMH on mental health, in all these schools. EEF will not measure the mental health effect of LTMH as that is out-of-scope for them. It would represent very good value to also learn mental health effects within the same study.
As a part of the mental health study, we aim to examine whether the LTMH program can improve student mental health, whether it works better for certain types of schools or students, and whether is offers a good value for money. We also aim to understand how it works, for whom and under what circumstances and how best it can be used in other settings, if needed. 
This study is nested within another study registered at https://www.isrctn.com/ISRCTN34801628

Who can participate?
All state-funded, mainstream secondary schools in England can take part in the study so long as the senior leadership team is able to commit to participation for the whole duration of the program and pay the participation costs.  

What does the study involve?
LTMH is a whole school program and involves training teachers to use a method call restorative practice. This differs from punishment-based methods by focusing instead on building relationships. It helps teachers model empathic conversation and manage conflict. The persons in a conflict can explain how they feel and take responsibility to find a way ahead. This helps heal relationships and prevents future problems. LTMH also involves setting-up of an ‘action group’ in each school, made up of teachers and students. Teacher and students work together to look at information collected from the students about their mental health alongside a manual with effective things to do for mental health. The action group then plan and make changes so the school feels more supportive.
To study the impact of the program on student mental health, students in year-7 or year-8 in all 140 schools will fill-out a questionnaire about their mental health (this will be collected as a part of the EEF study). Through random choice, 70 schools will then get the LTMH program, while 70 will carry on with their normal approach. Schools that get the LTMH program will get staff training for restorative practice, support to deliver action groups and a manual. We will make sure LTMH is inclusive and accessible to all students. Three years later, students in all 140 schools (now in year-10) will fill-out a questionnaire again. We will compare results to see if students in the schools that got the LTMH program report better mental health. We will also look at how much the program costs, and talk to teachers and students about their thoughts on LTMH. This will help us know whether LTMH works, whether it’s good value for money and whether it could be used in secondary schools across the country.

What are the possible benefits and risks of participating?
If LTMH works, it could be used in schools across England to help improve mental health for thousands of young people. We will share our findings widely with schools, teachers, parents, students, charities, policymakers and the government to make sure they lead to real change. Participating schools will also get some financial compensation for taking part. 
Risks of participation are minimal but may include individuals feeling upset about something while completing the questionnaires or interviews. We have protocols in place to provide support to participants if this should happen. 

Where is the study run from?
The mental health study is being led by a team of research from the London School of Hygiene &amp; Tropical Medicine and University College London. The study of educational impacts of the LTMH programme is being done by a team of researchers from Anna Freud and Ipsos. 

When is the study starting and how long is it expected to run for?
School recruitment for EEF’s large study on educational impacts began in March 2026 and is currently ongoing. The mental health study that we are embedding in this large study will use information collected from EEF’s study and will begin in September 2026.

Who is funding the study?
The embedded mental health study is funded by the National Institute of Health and Care Research, UK. The LTMH program is being funded by EEF as a part of their large study.

Who is the main contact?
Dr. Neisha Sundaram, London School of Hygiene &amp; Tropical Medicine</plainEnglishSummary>
      <primaryOutcomes>
	<outcomeMeasure id="0a5fc93e-04c6-46c1-9c79-697559125278">
	  <variable>Psychological difficulties</variable>
	  <method>Strengths and Difficulties Questionnaire (SDQ) Total Difficulties score</method>
	  <timepoints>Year 10 through endline surveys</timepoints>
	</outcomeMeasure>
      </primaryOutcomes>
      <primaryOutcome/>
      <secondaryOutcomes>
	<outcomeMeasure id="9c31fe1e-3169-4ac9-a004-9e45ecf95015">
	  <variable>Emotional problems, conduct problems, peer problems and hyperactivity</variable>
	  <method>SDQ subscales</method>
	  <timepoints>Year 10 through endline surveys</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="a3287bd6-d152-49e6-9ba6-9f8a4cf3b019">
	  <variable>Mental wellbeing</variable>
	  <method>Short Warwick-Edinburgh Mental Well-being Scale</method>
	  <timepoints>Year 10 through endline surveys</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="2ea76351-374a-4854-93ee-fa2ffae71ea3">
	  <variable>Eating problems and weight and shape cognitions</variable>
	  <method>Eating problems and weight and shape cognitions (EDE-QS)</method>
	  <timepoints>Year 10 through endline surveys</timepoints>
	</outcomeMeasure>
	<outcomeMeasure id="5efd1cd0-10e7-4237-9c8f-c655927313b9">
	  <variable>Bullying victimization</variable>
	  <method>Gatehouse Bullying Scale</method>
	  <timepoints>Year 10 through endline surveys</timepoints>
	</outcomeMeasure>
      </secondaryOutcomes>
      <secondaryOutcome/>
      <ethicsApprovalRequired>Ethics approval required</ethicsApprovalRequired>
      <ethicsCommittees>
	<ethicsCommittee id="b176e21f-4eb3-4849-8f5f-a9ae36d5e1ce" approvalStatus="notYetSubmitted">
	  <committeeName/>
	  <contactDetails>
	    <address/>
	    <city/>
	    <state/>
	    <country/>
	    <zip/>
	    <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	    <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
	  </contactDetails>
	  <committeeReference/>
	</ethicsCommittee>
      </ethicsCommittees>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18103637</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NIHR: 506643</protocolSerialNumber>
      <secondaryNumbers>
	<secondaryNumber id="cab0e580-adf3-455b-be42-d1314f5cf560" numberType="nihr" canonicalSecondaryNumber="NIHR506643">506643</secondaryNumber>
      </secondaryNumbers>
    </externalRefs>
    <trialDesign>
      <studyDesign/>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <interventionalTrialDesign>
	<allocation>Randomized controlled trial</allocation>
	<masking>Open (masking not used)</masking>
	<control>Active</control>
	<assignment>Cluster</assignment>
	<purposes>
	  <purpose>Prevention</purpose>
	</purposes>
      </interventionalTrialDesign>
      <secondaryStudyDesign>Not applicable</secondaryStudyDesign>
      <trialTypes/>
      <overallEndDate>2029-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>England</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b2b872f3-3664-40bb-a790-1fdbb48fd9c2">
	  <name>Schools in England</name>
	  <address>England</address>
	  <city>England</city>
	  <state/>
	  <country>England</country>
	  <zip>England</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes/>
      <healthyVolunteersAllowed>true</healthyVolunteersAllowed>
      <inclusion>1.	State-funded, mainstream secondary schools in England
2.	Senior leadership team (SLT) is able to commit to intervention, pay participation costs and sign Memorandum of Understanding
(The impact evaluation will include students in year 7 for schools that completed baseline surveys in the summer term of 2026, or students in year 8 for schools that complete  baseline surveys in the autumn term of 2026)</inclusion>
      <ageRange>Mixed</ageRange>
      <lowerAgeLimit unit="years" value="10.0">10 Years</lowerAgeLimit>
      <upperAgeLimit unit="years" value="70.0">70 Years</upperAgeLimit>
      <gender>All</gender>
      <targetEnrolment>140</targetEnrolment>
      <totalFinalEnrolment>0</totalFinalEnrolment>
      <exclusion>1.	The school’s most recent Ofsted rating is inadequate (based on the previous Ofsted grading). If the school has had an inspection since January 2026 with the new Ofsted grading criteria, schools that do not meet minimum safeguarding expectations and schools that receive an ‘urgent improvement’ grade in the ‘leadership and governance’ evaluation area will be excluded. Those schools will not be included, as the research has shown that schools require a minimum level of institutional capacity to implement the intervention.
2.	The school is enrolled in another mental health or wellbeing intervention study. Note that schools involved in descriptive surveys or small pilot projects (e.g. with psychology students) will not be excluded
3.	The school is enrolled in any other EEF trial currently that is also focused on mental health
4.	The schools involved in the LTMH feasibility study</exclusion>
      <recruitmentStart>2026-03-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2026-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStartStatusOverride/>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Preventing mental health problems and improving wellbeing among secondary school students</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study involves a cluster randomised controlled trial (RCT) to examine the effectiveness, cost-effectiveness and mechanisms of the 'Learning Together for Mental Health' (LTMH) program in terms of its mental health outcomes for students, nested within the Education Endowment Foundation (EEF)'s trial assessing the impact of LTMH on educational outcomes. 

As part of the EEF trial, all pupils in Year 7 (Spring/Summer 2026) or Year 8 (Autumn 2026) in 140 schools will be invited to take part in an online survey completed in school. Schools are the unit of randomisation and are allocated on a 1:1 basis to the intervention and control arms, stratified by school-level factors: school-level deprivation (% students eligible for FSM below or above the median in England for the year); special education needs (SEN) status (proportion of students with SEN and disabilities); and attainment (Progress 8 score school average above and below median of 0 for England), by a researcher not involved in the statistical analysis from the Education Trial evaluation team. A first set of schools that completed ≥ 80% of responses on the baseline survey by the end of the summer term 2026 were randomised simultaneously in a block in late July 2026. Schools that complete their baseline surveys after this are being randomised on a weekly rolling (sequential) basis.

Intervention:
Learning Together for Mental Health (LTMH) is a whole-school, multicomponent, facilitated intervention that involves four key elements in each school.
a) Formation of student and staff co-led Action Group (AG). It is empowered to modify school mental health and disciplinary policy. The AG will be facilitated by Place2Be staff. The AG will meet twice per term across each year of implementation, meeting more frequently if needed. The AG can draw on the following: (i) A student needs assessment report (NAR), drawing on the instruments and measures included in the baseline student survey. This provides the AG with data on their school’s prevalence of various needs, such as psychological problems, conduct problems, peer relationship problems, self-harm, eating problems, bullying, substance use and anti-social behaviour; (ii) An intervention manual including an evidence-based menu of effective mental health actions and strategies at the school level which have been previously shown to improve aspects of menatal health and wellbeing in young people. The Place2Be facilitator will guide the AG in using the menu and selecting actions from the menu that address the priorities identified for the school. The manual will also provide guidance on setting up and running inclusive AGs.
b) Facilitation: The AGs are facilitated by a trained facilitator with expertise in school mental health, employed, supervised and trained by Place2Be. Place2Be will employ a lead facilitator who will manage and supervise these facilitators. Each school will receive seven half-day sessions of in-person facilitation in the first year of implementation and six sessions in the second year, supported by the same facilitator across the intervention. Online support from facilitators will be available to schools between in-person visits. In the third year of implementation, AG chairs will facilitate the AGs, supported by Place2Be where required. 
c) All-staff introductory training in restorative practice (RP) which aims to prevent and address conflict and thereby improve mental health via improving relationships. All staff are trained to implement primary RP through empathic communication and working ‘with’ students. 
d) In-depth training in RP for selected staff to facilitate meetings in which bullying victims are empowered to communicate harms, while perpetrators are encouraged to acknowledge these and take responsibility for their behaviour to repair relationships and prevent future conflict, thus contributing to improved mental health. 

The intervention will be a three-year programme, fully facilitated by Place2Be for the first two years and with light-touch support for schools from Place2Be in year 3. Schools will be encouraged to continue implementation independently in a fourth year, after which the educational evaluation will take place.

Control:
Control schools will continue their usual practice regarding existing relationships, sex and health education and mental health provision to maximise trial external validity

A process evaluation (PE) will be conducted to explore mechanisms underlying mental health impacts and implementation. For this, in four case study schools, two staff members will be invited to participate in interviews every year for three years of the intervention. Students will also be invited to participate in two student focus groups per year of the intervention in each of the four case-study intervention schools.</description>
	<interventionType>Behavioural</interventionType>
	<phase/>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not expected to be made available</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <funderId>ee405987-105e-4f45-b0f6-86d0687ed655</funderId>
      <contactId>28327406-ca08-41d3-91c3-b26cc864b31d</contactId>
      <contactId>1451ff06-9e7e-492e-a868-5682c9b8270f</contactId>
      <sponsorId>254155fd-3877-47a0-b530-63e46bae3867</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="28327406-ca08-41d3-91c3-b26cc864b31d">
    <title>Dr</title>
    <forename>Neisha</forename>
    <surname>Sundaram</surname>
    <orcid>https://orcid.org/0000-0003-4159-9518</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
      <contactType>Public</contactType>
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>15-17 Tavistock Place
London School of Hygiene &amp; Tropical Medicine</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1H 9SH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 8636</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">neisha.sundaram@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <contact id="1451ff06-9e7e-492e-a868-5682c9b8270f">
    <title>Prof</title>
    <forename>Russell</forename>
    <surname>Viner</surname>
    <orcid>https://orcid.org/0000-0003-3047-2247</orcid>
    <contactTypes>
      <contactType>Principal investigator</contactType>
    </contactTypes>
    <contactDetails>
      <address>University College London, UCL Great Ormond St. Institute of Child Health, UK, 30 Guilford St.</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>WC1N 1EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0) 20 7679 2000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.viner@ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="254155fd-3877-47a0-b530-63e46bae3867">
    <organisation>London School of Hygiene &amp; Tropical Medicine</organisation>
    <sponsorType/>
    <rorId>https://ror.org/00a0jsq62</rorId>
    <commercialStatus>Non-commercial</commercialStatus>
  </sponsor>
  <funder id="ee405987-105e-4f45-b0f6-86d0687ed655">
    <name>National Institute for Health and Care Research</name>
    <fundRef>http://dx.doi.org/10.13039/501100000272</fundRef>
  </funder>
</fullTrial></allTrials>